Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Host microbiomes in tumor precision medicine: how far are we?

(Article begins on next page)

25 April 2024

1 **Host microbiomes in tumor precision medicine: how far are we?**

2 Federica D'Amico[1,2], Monica Barone[1,2], Teresa Tavella[2], Simone Rampelli[2], Patrizia Brigidi[1] and Silvia Turroni[2,*]

3

4 [1] Microbiome Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy

5 [2] Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna,

6 Bologna 40126, Italy

7 * Corresponding author: Silvia Turroni, PhD, Senior Assistant Professor, Unit of Microbiome Science and Biotechnology,

8 Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy. e-mail:

9 silvia.turroni@unibo.it

10

11 **Abstract**

12 The human gut microbiome has received *a crescendo* of attention in recent years, due to the countless influences on

13 human pathophysiology, including cancer. Research on cancer and anticancer therapy is constantly looking for new hints

14 to improve the response to therapy while reducing the risk of relapse. In this scenario, the gut microbiome and the plethora

15 of microbial-derived metabolites are considered a new opening in the development of innovative anticancer treatments

16 for a better prognosis. This narrative review summarizes the current knowledge on the role of the gut microbiome in

17 ~~cancer~~ the onset and progression of cancer, as well as in response to chemo-immunotherapy. Recent findings regarding

18 the tumor microbiome and its implications for clinical practice are also commented on. ~~The c~~Current microbiome-based

19 intervention strategies (*i.e.*, prebiotics, probiotics, live biotherapeutics and fecal microbiota transplantation) are then

20 discussed, along with key shortcomings, including ~~the~~ a lack of long-term safety information in patients who are already

21 severely compromised by standard treatments. ~~In this scenario~~Thus, the implementation of bioinformatic tools applied to

22 microbiomics and other omics data, such as machine learning, has an enormous potential to push research in the field,

23 ~~allowing~~ enabling the prediction of health risk and therapeutic outcomes, for a truly personalized precision medicine.

24

25

26

27

28

29

30

31

1

33

Graphical Abstract

35

Personalized microbiome-based interventions are critical ~~to~~ ~~for ensure~~ ensuring antitumor immune responses, circumventing resistance to chemo-immunotherapy.

38

Keywords: Gut microbiome, Microbial metabolites, Tumor microbiome, Anticancer therapy, Probiotics, Fecal microbiota transplantation, Next-generation probiotics, Machine learning

41

42

43

44

45

46

47

48

49

1. Introduction

In recent years, the microbial community inhabiting the gastrointestinal tract (*i.e.*, the gut microbiome – GM) has received special attention, not only for the well-known supporting functions of host homeostasis [1,2], but also for its involvement in the onset and progression of cancer, as well as in the outcomes of anticancer therapy [3]. Tumor development and patient failure to response to anticancer approaches (*i.e.*, chemotherapy, radiotherapy, and immunotherapy) are among the leading causes of death worldwide [4]. For this reason, research is moving towards new fields that could help overcome these obstacles; host-associated microbes, as well as their products, have recently been identified as unexpected key orchestrators in these branches.

Herein, we discuss the role of GM composition and functionality in promoting the development and progression of local and distant tumors, as well as recent evidence on the intratumor microbiome. Particular attention is given to immunological tumors (e.g., leukemia and lymphoma) and to complications related to hematopoietic stem cell transplantation (HSCT), for which an abundant and consistent microbiome-centered literature is available.

In attempt to fully explore the possibility of using microorganisms/microbiomes as a therapeutic target/tool in the anticancer field, we comment on microbiome-tailored intervention strategies currently in use, as well as the most recent clinical trials involving the use of prebiotics, (traditional and next-generation) probiotics and fecal microbiota transplantation (FMT). Finally, we discuss the translational potential of bioinformatics, particularly machine learning, to stratify patients, predict outcomes, and design personalized precision intervention strategies for a better patient quality of life. See **Figure 1** for a summary of the role of host microbiomes in tumor onset and progression, as well as in response to therapy, and the available microbiome manipulation tools that could help improve patient prognosis.

2. Exploring the human gut microbiome and its functions from eubiosis to dysbiosis

The GM is a key contributor to maintaining the host physiological homeostasis [1,2]. While this sentence may seem foregone in 2021, countless studies still attempt to advance our understanding of the close and complex relationship between the GM and the human host. Going back in time, the first signs of the presence of microbes inside the human intestinal tract took place in the late 1800s in Europe, when the German pediatrician Theodor Escherich consolidated the study of "human gut flora" [5,6]. Indeed, Prof. Escherich discovered what he called "*Bacterium coli commune*" (*i.e.,* currently *Escherichia coli*) in human feces and afterwards "*Bacillus bifidus communis*" (*i.e.*, *Bifidobacterium animalis*) in the gut of newborns and breast-fed infants. For the first time, Escherich and colleagues

spoke of "good bacteria" ~~in a period in which~~at a time when the only link between microorganisms and their host was in the development of ~~pathologies~~ diseases (e.g., cholera, anthrax and tuberculosis) [5]. From then to the present day, GM research has always played an important role in science.

GM is a deeply complex ecosystem that includes not only bacteria, which are the most represented, but also archaebacteria and fungi, along with viruses [7]. Until recently, a frequently repeated slogan was that the human body contained 10 times more microorganisms than human cells. However, this was a rough calculation made more than 40 years ago [8], while today we can state that the ratio of human to microbial cells is likely to be 1:1 with the balance slightly in favor of microbes [9]. As just mentioned, the most examined fraction of GM is the bacterial one, 90% of which belongs to Firmicutes and Bacteroidetes phyla, while the remaining 10% is distributed among the subdominants Actinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia [2]. So far, it is estimated that the collective genome of GM, known as the microbiome, harbors 150 to 500 times more genes than the host, which are implicated in providing functional traits that complement the human repertoire and ~~that~~ are relevant to our metabolic, immunological and neurological homeostasis [10-12].

In the individual's lifespan, the first microbial stimuli derive from the early moments of the infant's life and are closely linked to the birth mode, the maternal microbiota, antibiotic exposure and early-life feeding practices [13,14]. At this time, when ~~the~~ infant-GM symbiosis is ~~going to~~ being established, GM is featured by low bacterial diversity and functional complexity, as well as a higher degree of interpersonal variation ~~compared to~~than the adult-type GM profile [15,16]. Both structural components of microbes and products of their metabolism have been found to be involved in the development, maturation, and education of the child's immune system [17-19], as well as in the regulation of the endocrine and central nervous systems [20]. It is therefore not surprising that GM disruption (*i.e.*, dysbiosis) ~~during~~in the early- life ~~window~~ ~~can~~ may be associated with several disorders [21,22], such as type 1 diabetes, atopic disease, asthma and childhood obesity [23-25]. At weaning, with the cessation of breastfeeding, there is a rapid increase in the ~~the~~ structural and functional diversity of the infant GM, which progressively evolves towards ~~the~~ a mature adult-like state [26]. The development of the adult GM is regulated by a complex interplay between the host and several environmental factors, such as diet, lifestyle, or the so-called geographical effect [27,28] or, more generally, the exposome (*i.e.*, the totality of internal and external exposures that an individual faces throughout his life) [29]. ~~In~~ Under healthy conditions, all of these factors contribute to shaping the microbial community, selecting a eubiotic GM configuration (*i.e.,* a stable, resistant, and resilient GM, with high diversity and functional redundancy) [30], which provides the functional traits necessary for host homeostasis, such as the barrier effect against infectious threats and the production of several bioactive small molecules that support the GM-host metabolic, immunological and neurological connections (e.g., vitamins, fatty acids, protein metabolites, bile acids, polyamines, etc.) [31-33].

4

112 As a matter of fact, GM is dominated by species (mainly from *Ruminococcaceae* and *Lachnospiraceae* families) capable

113 of degrading complex carbohydrates, otherwise indigestible for humans, such as glycans and mucins (called Microbiota-

114 Accessible Carbohydrates) [34]. The end products of this fermentation are short-chain fatty acids (SCFAs) [13], mainly

115 acetate, propionate and butyrate, which are indisputably beneficial to health, acting as local (butyrate) and peripheral

116 (acetate and propionate) energy sources, inflammation modulators, vasodilators and regulators of gut motility, wound

117 healing, metabolism and epigenetics [35]. SCFAs also influence the proliferation and differentiation of colonic epithelial

118 cells, including through the modulation of gene expression, and contribute to the protection against pathogens, promoting

119 the integrity of the epithelial barrier, acidifying the intestinal milieu and stimulating the production of bacteriophages [36-

120 39]. At the systemic levelSystemically, SCFAs act as signaling molecules that drive the expansion and function of

121 hematopoietic and non-hematopoietic cell lineages [35]. For example, SCFA-mediated inhibition of histone deacetylase

122 promotes tolerogenic and anti-inflammatory functions that are crucial for the maintenance of immune homeostasis

123 [19,33]. Many other immunoregulatory properties of SCFAs are associated with the activation of G protein-coupled

124 receptors expressed by nearly all types of immune cells, including epithelial cells, neutrophils, monocytes and

125 macrophages [40,41].

126 Another worthy example of GM-produced metabolites that act as key immunoregulators are polyamines (e.g., putrescine,

127 spermine, and spermidine), which are usually produced by amino acid decarboxylases [42]. These molecules are essential

128 for host cell function, barrier integrity and pathogen defense against pathogens, as well as for local and systemic adaptive

129 immunity [43-46]. Alterations in polyamine metabolism with higher levels of these compounds have been shown to be

130 associated with cell growth bugs, and acute and chronic inflammation up to carcinogenesis [47]. Indeed, highly

131 proliferative cells, such as tumor cells, require polyamines, among others, to support rapid growth. For example, increased

132 circulating and urinary levels of polyamines have been observed in patients with colorectal cancer (CRC), as well as with

133 skin and hormone-related (*i.e.*, breast and prostate) tumors cancers [49-50]. As recently demonstrated, a "polyamine

134 blocking therapy", based on the reduction of intratumoral polyamine availability, could therefore have an antiproliferative

135 effect but also reverse immunosuppression in the tumor microenvironment and heighten antitumor immune responses

136 [51,52]. On the other hand, it should be mentioned that in autophagy-competent tumors, treatment with spermidine (as an

137 autophagy-inducing caloric restriction mimetic) improved the efficacy of anticancer chemotherapy and enhanced

138 immunosurveillance [53].

139 Not only the metabolites produced or contributed by GM but also the structural components of the microbes are able to

140 influence the host immunological landscape. Since birth, the human immune system coexists with a plethora of

141 microorganisms and develops pattern recognition receptors (PRRs), capable of detecting microbe-associated molecular

142 patterns (MAMPs) (e.g., lipopolysaccharide (LPS), peptidoglycan, flagellin and unmethylated bacterial DNA CpG

143   motifs) [54]. This intimate GM-immune system crosstalk is strategic for maintaining the delicate balance between

144   tolerance towards commensal microbes and recognition and attack towards pathogens or pathobionts [32,55]. Upon PRR-

145   mediated response activation, a complex signaling cascade is initiated ~~that~~ lead~~s~~ing to the release of host immune system

146   effectors, such as cytokines, chemokines, and acute phase proteins [56,57]. Furthermore, MAMPs are involved in the

147   modulation of immune cell function, such as neutrophil migration and function [58] and differentiation of T cell

148   populations into helper cells (T$_H$) (*i.e.,* T$_H$1, T$_H$2 or T$_H$17) or T regulatory cells (T$_{reg}$) [54]. For example, in preclinical

149   models, *Bacteroides fragilis*-specific structural polysaccharide (PSA) has been shown to restore a T$_H$1/T$_H$2 imbalance

150   through stimulation of Toll-like receptor (TLR) 2 signaling and interleukin (IL)-12 production by dendritic cells, and

151   suppress inflammation by driving IL-10 production [59,60].

152   As mentioned above, during human lifespan, GM is able to respond and adapt to changes in endogenous and exogenous

153   variables, such as diet, lifestyle and geography. This is made possible by the great GM plasticity, *i.e.*, the ability to oscillate

154   between different healthy states, without losing diversity, stability, as well as ~~and~~ microbe-microbe and microbe-host

155   interactions [30]. However, it is also well known that ~~in~~ under certain conditions, such as intake of antibiotics or other

156   drugs, pathogen infection and inflammation, just to name a few, stability is compromised and unbalanced (dysbiotic)

157   states are established, which can be resilient and explain the onset and progression of diseases, as well as resistance to the

158   ~~efficacy~~ effectiveness of treatments [12]. Although the exact boundaries of a healthy GM are still ~~lacking~~ missing [61],

159   disease-associated GM profiles are typically featured by less biodiversity and distinct compositional alterations, which

160   fall~~ing~~ into the following categories: selective suppression of certain health-associated members (generally SCFA-

161   producing, oxidative stress-sensitive *Lachnospiraceae* and *Ruminococcaceae* taxa) and/or burst of subdominant taxa,

162   including overt pathogens or pathobionts [62]. These alterations are generally reflected in an inappropriate pattern of

163   metabolites, which can improperly regulate human biology, with even deleterious consequences for health [63,33].

164

165   **3. The gut microbiome in cancer development and progression**

166   *3.1 The role of the gut microbiome ~~role~~ in ~~the~~ tumor onset: CRC and beyond*

167   ~~Until now,~~So far unhealthy states of GM have been found in the context of multiple intestinal but also metabolic,

168   immunological, hepatic, respiratory, cardiovascular, neurological, psychiatric, and oncological disorders [3]. In most

169   cases, it is still impossible to define whether or not GM has a causative role ~~or not~~, even if some hypotheses supporting

170   ~~causality~~ causation have been advanced, especially in obesity and related complications [64]. Notwithstanding this, it

171   must be said that for some disorders, the related literature is already quite substantial (e.g., for inflammatory bowel disease

172   (IBD) and CRC) [65-67], while for others, such as different tumor types, there is still a long way to go to understand the

GM-disease relationship. As expected, the loss of intestinal homeostasis has been linked to both local (*i.e.*, CRC and gastric cancer) [68,69] and distant tumors, such as pancreatic [70], laryngeal [71] and gallbladder [72] carcinomas.

To date, microbial pathogens are known to drive 20% of carcinogenesis [73,74]. Carcinogenesis is a multistep process, ~~whose~~ the progression of which is characterized by the gradual accumulation of slow and random genetic and epigenetic mutations that can take more than 10 years depending on the frequency [75]. In particular, as far as the GM field is concerned, the most frequent (and obvious) connection has been made with CRC. CRC is sporadic ~~for~~ in approximately 90% of cases and develops gradually from normal epithelium to adenomatous polyps until the settlement of an invasive carcinoma [76]. In addition to genetic predispositions that can increase the risk of developing CRC (e.g., adenomatous polyposis coli gene mutation), leading to the development of hundreds to thousands of polyps, several environmental factors have been shown to be involved in CRC onset, including diet, chronic inflammation (e.g., IBD) and GM [77]. As for the latter, several studies have ~~shown~~ highlighted a CRC-associated GM profile enriched with opportunistic pathogens, such as *Fusobacterium*, several members of the *Enterococcaceae* family and *Campylobacter*, as well as other pro-inflammatory taxa*, i.e.*, *Erysipelotrichaceae* and *Collinsella* (recently proposed as a potential marker of metabolic disorders) [78-81]. In parallel, a reduction ~~of~~ in health-associated microbial partners, including the butyrate producers *Faecalibacterium* and *Roseburia*, is frequently observed [82]. However, all of these studies, although milestones in the CRC-associated GM literature, are purely observational and ~~have~~ therefore have not explored the mechanisms by which GM members can influence CRC or, more importantly, the triggers that shift the GM profile towards a tumor-associated one. Most of these questions were answered by coupling next-generation sequencing-based approaches with animal models, which helped to better outline the role of GM microbes in tumor onset. Research conducted in recent years has highlighted the fairness of the bacterial driver-passenger model developed in 2012 ~~from~~ by Tjalsma et al. [83] Briefly, several environmental (e.g., diet, pathogen infection) and genetic (e.g., chronic inflammation, mutations) factors can push the GM homeostatic profile towards a dysbiotic, pro-inflammatory one that settles in the gastrointestinal tract. CRC can therefore be promoted by commensal bacteria with pro-carcinogenic features (known as bacterial drivers) that drive the DNA damage of the colon epithelium, leading to CRC development. Afterwards, the local microenvironment is altered as a result of ongoing inflammation and carcinogenesis, which paves the way for bacterial passengers, *i.e.*, microorganisms that show a competitive advantage in the tumor microenvironment and allow for cancer progression [83]. Therefore, inflammation is a trigger for initiating the GM-dependent pro-inflammatory cycle, which is detrimental to the host health [69]. The bacterial drivers identified so far are mostly subdominant components of GM, capable of inducing a harmful inflammatory loop, synthesizing genotoxins and other toxic molecules that can directly damage host cells, and activating dietary heterocyclic amines to pro-carcinogens [69]. ~~Some e~~Examples ~~are~~ include superoxide-producing *Enterococcus faecalis* strains [84,85], toxigenic strains belonging to the *B. fragilis* species [86,87], and genotoxin-

7

producing *Salmonella enterica* and *E. coli* strains [88-91]. As for bacterial passengers, again ~~they~~ these are usually subdominant GM commensals, which may however show either tumor-promoting or tumor-suppressive properties, depending on the microorganism type. Indeed, ~~the~~ tumor tissue is selectively colonized by opportunistic pathogens, such as *Clostridium septicum* [92], *Fusobacterium nucleatum* [93], *Streptococcus gallolyticus* [94], and several *Enterobacteriaceae* members [83], but sometimes also ~~sometimes~~ enriched in health-associated bacteria, such as *Roseburia* and *Faecalibacterium*, for which a possible protective role as CRC quenchers has been advanced [95].

It is clearly very simple to explain the relationship ~~of~~ between GM ~~to~~ and CRC, but the pro-carcinogenic role of commensal microbes extends far beyond the gastrointestinal tract [74,96]. Due to its physical proximity and close physiological links, the liver is one of the organs most affected by GM. The development of hepatocellular carcinoma (HCC) may be related to various GM-derived functions and metabolites, including LPS, ~~whose~~ the presence of which potentiates HCC tumorigenesis through the activation of innate immune system effectors, such as TLR4 [97]. Moreover, some GM taxa play the role of oncogenic drivers by producing secondary bile acids (*i.e.,* deoxycholic acid, DCA), deriving from ~~the~~ GM-mediated deconjugation and metabolism of primary bile acids [98]. Once absorbed from the gastrointestinal tract, DCA can reach the liver through the portal circulation, where it can exert tumorigenic functions by inducing DNA damage and senescence on hepatocytes, with the establishment of a pro-inflammatory liver environment [99,100]. Consistently, in murine models fed high-fat diets, ~~it has been observed that the~~ enrichment of GM species belonging to the *Clostridium* genus, including *C. scindens*, *C. hiranonis*, *C. hylemonae* and *C. sordelli*, capable of producing DCA [101], led to progression from non-alcoholic steatohepatitis to HCC [99]. The same tumor-driving actions by GM members have recently also been reported in esophageal tumors [100]. Finally, it is worth mentioning that GM dysbiosis and the consequent dysregulation of metabolite production have been shown to be involved in the development of breast cancer [102,103]. In particular, gut microbes are able to metabolize liver-derived estrogens through beta-glucuronidase and beta-glucosidase activities in the gastrointestinal tract (the so-called estrobolome, *i.e.*, "the aggregate of enteric bacterial genes whose products are capable of metabolizing estrogens") [104]. This GM role in modulating the systemic ~~estrogen~~ pool of estrogens could affect their enterohepatic circulation and reabsorption, thus contributing to an increased risk of hormonal cancers, such as breast cancer [105-107].

3.2 Gut microbiome middles with anticancer therapies

A new frontier of research is the understanding of the bidirectional relationship between GM and drugs (*i.e.*, pharmacomicrobiomics) [108]. GM can in fact modulate the host response to therapies through several mechanisms, including immune system interactions and drug metabolism [109], and, in turn, drugs can affect the GM structure and thereby its mutualistic relationship with the host [110]. Identifying the pivots of this relationship can therefore be crucial

235 for improving patients' clinical outcomes, as it can inform the development of novel, evidence-based intervention

236 strategies, aimed at manipulating GM to enhance therapeutic efficacy, reduce toxicity and possibly, also the risk of relapse

237 [111,112].

238 The first research on GM in anticancer therapies dates back to 1890, when two heat-inactivated microbes belonging to

239 the *Streptococcus* genus were injected intratumorally as an attempt to cure cancer in humans. In those years, Dr. Coley

240 thought that a local bacterial infection could boost the patient immune response against inoperable tumors. For more than

241 40 years, more than 1000 patients were injected intratumorally with microbes or microbial products, with excellent results

242 mostly in inoperable bone and soft-tissue sarcomas. From this moment on, albeit rudimental, this approach was called

243 Coley's Toxins and defined as the "father of immunotherapy" [113,114]. Several years later, the same approach was used

244 to treat patients with bladder cancer, in whom *Mycobacterium bovis* was intratumorally injected right after tumor

245 resection, resulting in reduced tumor recurrence through activation of local immune responses [115]. Furthermore, oral

246 administration of the well-known probiotic species *Lactobacillus casei* has been associated with the decrease in recurrence

247 of superficial bladder cancer [116]. Later on, all these studies confirmed the intuition of those researchers: the antitumor

248 responses were stimulated by the microbial activation of two important effectors of the immune system: natural killer

249 cells and macrophages [117]. Although these are rudimentary and "seasoned" studies, they have paved the way for many

250 clinical trials, some still ongoing, using attenuated GM members to aid cancer treatments [118]. Recently, ~~it has been~~

251 ~~observed that~~ *Mycobacterium obuense* [119,120] and genetically modified *Salmonella* Typhimurium [121,122] have been

252 shown to promote anticancer responses in several refractory solid tumors (e.g., pancreatic, melanoma), by activating the

253 host immune system and exerting a cytotoxic effect on tumor cells. While very promising, many studies are still needed

254 to refine microbial therapies before they can be used in clinical routine. Still today, the action and toxicity of microbes

255 inside the tumor are very hazy and mainly correlated to the long microbial half-life with the possibility of antibiotic

256 resistance accumulation, as well as the onset of mutations reverting the attenuated bacterial phenotype [123].

257 In addition to the intratumoral effect of individual microbes, the GM has recently been associated with the therapeutic

258 outcome of anticancer treatments [124]. Since the discovery of the cytotoxic effects of mustard gas during the Second

259 World War, cytotoxic chemotherapeutic ~~cytotoxic~~ agents (*i.e.*, alkylating agents, platinum-based drugs and cytotoxic

260 antibiotics) have been developed and are still the major staple of anticancer approaches [125]. However, some ~~tumors~~

261 cancers fail to respond to treatment and/or ~~tumor~~ the cancer relapse ~~oc~~recurs. To overcome these hurdles, novel anticancer

262 approaches are constantly in progress [126]. The first advancement in this field was the development of targeted

263 immunotherapy [127,128] and, of course, research focusing on the relationship between GM ~~and~~ anticancer therapy has

264 ~~relationship~~ followed the same trend. Gut microbes have been shown to influence drug pharmacokinetics, anticancer

265 activity and toxicity of chemo-immunotherapy treatments to varying degrees [110,129]. A striking example of a GM-

9

266 drug interaction is represented by irinotecan, a chemotherapy drug administered parenterally in an inactive form to

267 patients with CRC, which is activated by host enzymes, detoxified in the liver and subsequently excreted in the intestinal

268 lumen via the bile [130]. Here, GM members can reverse the detoxification process through bacterial beta-glucuronidases,

269 which catalyze drug deconjugation and reactivation, resulting in intestinal toxicity [131]. In this regard, the use of specific

270 enzyme inhibitors has been shown to prevent irinotecan-induced diarrhea while maintaining its efficacy in animal models

271 [132]. As for the GM influence on anticancer activity, one of the first milestone studies in the field showed that the

272 antitumor effect of oxaliplatin or cisplatin treatment on subcutaneous transplantable tumors was ~~dramatically~~ drastically

273 reduced in germ-free or GM-depleted mice by broad-spectrum antibiotics [133]. The so-called platinum resistance of

274 these models has recently been linked to the role of GM members in promoting oxidative stress and, subsequently,

275 apoptosis of ~~tumor~~ cancer cell ~~apoptosis~~. Consistently, mice with lung tumors treated with antibiotic-coupled cisplatin

276 therapy have been shown to have reduced long-term survival and developed even larger tumors [134]. On the other hand,

277 when cisplatin was combined with the administration of probiotics, ~~like~~ such as *Lactobacillus acidophilus,* the same

278 animal models showed improved response to chemotherapy, through the activation of pro-apoptotic genes and effectors

279 within the tumor aggregate and the promotion of a proper tumor-specific immune response. Similar to platinum-derived

280 compounds, chemotherapy treatments based on the alkylating agent cyclophosphamide coupled with ~~the~~ oral

281 administration of microbes (*i.e.*, *Lactobacillus johnsonii* and *Enterococcus hirae*) have been shown to promote the

282 conversion of T cells from naïve to pro-inflammatory T_H17, with the final outcome of improved therapeutic efficacy in

283 tumor-bearing mice [135-137]. These findings were also confirmed in advanced lung or ovarian cancer studies, in which

284 patients with GM enrichment of *E. hirae* and *Barnesiella intestinihominis* showed a more favorable prognosis after

285 chemo-immunotherapy [138].

286 With specific regard to immunotherapy, different studies have highlighted that the administration of CpG

287 oligodeoxynucleotides (*i.e.,* synthetic molecules mimicking microbial DNA) strongly stimulated the host immune system,

288 pushing endogenous anticancer activity in several types of cancer [139]. After *in vivo* intratumoral injection of CpG

289 oligodeoxynucleotides coupled with anti-IL-10 receptor antibody, ~~the~~ host immune cells were activated near the tumor

290 site to produce pro-inflammatory tumor necrosis factor (TNF), leading to reduced tumor growth due to hemorrhagic

291 necrosis. ~~With~~ By a similar mechanism, the administration of *Alistipes shahii* and *Ruminococcus* in antibiotic-treated

292 mice stimulated the production of TNF with a notable improvement of the anticancer therapeutic outcomes [133]. As the

293 literature currently stands, GM members are involved in the intrinsic efficacy of another class of immunotherapy drugs

294 known as immune checkpoint inhibitors, which are commonly used to treat different types of solid tumors. These

295 molecules are capable of blocking immune-inhibitory pathways, thus modulating the activation of T cells against the

296 targeted tumor cells [140-142]. Currently, the checkpoint inhibitors put in place are monoclonal antibodies that target

cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death 1 (PD1) located on T cell surfaces, as well as its ligand (*i.e.,* programmed cell death ligand 1, PD-L1) [143]. The mechanisms of action are both T cell-specific but while anti-CTLA4 therapy is able to regulate T cell proliferation early during the immune response within the lymph nodes, anti-PD1 suppresses T cell activation later in the body periphery [144]. In this scenario, a landmark study by Vétizou and colleagues [145] showed that antibiotic-treated or germ-free mice with subcutaneous tumors treated with anti-CTLA4 responded poorly to therapy, but the response was significantly increased when GM was enriched in *Bacteroides fragilis* and *Burkholderia cepacia* [145]. Furthermore, oral feeding of GM-depleted mice with different *Bacteroides* species (*i.e.*, *B. thetaiotaomicron* or *B. fragilis*) restored the therapeutic response to anti-CTLA4 by inducing immune cell response in tumor-draining lymph nodes. When *B. fragilis* and *B. cepacia* were administered together in the same murine models, *B. fragilis and B. cepacia were administered together*, the restoration of the anti-CTLA4 response was confirmed but, unlike the administration of single *Bacteroides* taxa, therapy-related side effects, such as intestinal damages and colitis, were also significantly reduced. These findings were confirmed upholded in melanoma patients treated with anti-CTLA4, where the abundance of the Bacteroidetes phylum was positively correlated with the reduction in of therapy-associated colitis. In particular, the GM profiling of these patients revealed three different configurations: one was dominated by *Prevotella* spp., whereas the other two were mostly characterized by the presence of various *Bacteroides* spp. Subsequently, these different GM configurations were used to perform FMT to on germ-free mice. Only the GM profile enriched in *B. thetaiotaomicron* or *B. fragilis* resulted in high responsiveness to anti-CTLA4 treatment in non-responder mice. Taken together, these observations are extremely relevant as they suggest not only that some GM members may affect immunotherapy responses but also that GM manipulation may favor antitumor activity in non-responders. On the same line of as anti-CTLA-4 therapy, Sivan et al. found that in melanoma-bearing mice, the efficacy of PD-L1-targeted antibodies was enhanced in the presence of a GM ecosystem enriched with different *Bifidobacterium* spp., including *B. breve*, *B longum* and *B. adolescentis* [146]. Oral administration with a commercially available probiotic cocktail (*i.e.*, with *B. breve* and *B. longum*) during anti-PD-L1 therapy, was able to activate the immune T cell response and hold tumor growth, while the combined treatment (bifidobacteria and anti-PD-L1) nearly abolished tumor outgrowth. From this moment onwards, multiple translational works have been carried out. Among the most relevant, it is certainly noteworthy that of Routy et al., [140] who found that patients with melanoma treated with antibiotics during anti-PD-L1 immunotherapy showed a lower survival rate [140]. By comparing the GM of responders vs non-responders, the authors were able to identify the GM compositional signatures of response to therapy, which consisted of an enrichment in *Akkermansia* and *Alistipes*. Again, they performed FMT from patients to germ-free mice and found that *Akkermansia muciniphila*, alone or in combination with *E. hirae*, increased intratumoral cytotoxic T cell infiltrates, favoring the PD-1 blockade response. In parallel, similar compositional differences between responders and non-responders to anti-PD-L1

11

therapy were found out by Gopalakrishnan et al. [141]. Notably, responders to melanoma-targeted therapy were characterized by higher microbial diversity, as well as increased relative abundance of *Ruminococcaceae* and *Faecalibacterium*, both associated with improved effector T cell function in the peripheral and intratumoral environment. On the other hand, patients showing poor immunotherapeutic response possessed lower microbial diversity and higher relative abundance of Bacteroidales, which ~~was~~ correlated with reduced systemic and antitumor immune responses. Another GM metagenomic characterization in patients with melanoma treated with immune checkpoint inhibitors further corroborated the above findings (*i.e.*, that responders have a distinct GM profile from non-responders), although in this case the efficacy of anti-PD-L1 therapy was associated with *B. longum*, *E. faecium* and *Collinsella aerofaciens* [142].

It should be noted that, despite the huge number of microbial species inhabiting the gastrointestinal tract, to date only a few of them have been suggested to play a role in anticancer responses and only a handful of strains have shown the potential to manipulate ~~the~~ host physiological functions *in vivo* [147,148]. For example, Tanoue and colleagues [149] isolated a consortium of 11 microbial strains (mainly belonging to *Bacteroides* spp.) from feces of healthy human donors, which are able to robustly induce T cell activation within the intestine. *In vivo* colonization with the 11-strain mixture enhanced the therapeutic efficacy of immune checkpoint inhibitors in syngeneic tumor models, confirming the great potential of these microbes as widely effective biotherapeutics in anticancer approaches. Furthermore, three strains belonging to *B. pseudolongum*, *L. johnsonii*, and *Olsenella* have recently been tested in tumor-bearing mice, where they significantly increased the efficacy of immune checkpoint inhibitors [150]. In particular, *B. pseudolongum* enhanced the immunotherapy response through the production of the metabolite inosine, which was able to systemically translocate due to immunotherapy-induced decrease in gut barrier function, and thus activate antitumor T cells. Several questions about the safety of administering live microbes to very often immunocompromised patients during anticancer therapy have been raised over the years and are still largely unanswered. In this context, the usage of prebiotics could be a valid alternative, as discussed below (see the paragraph "Modulation hypothesis: prebiotics, probiotics, live biotherapeutics and FMT, as adjuvant cancer therapy"). As an example, prebiotics (*i.e.,* mucin and inulin) have been shown ~~in syngeneic mouse models~~ to induce antitumor immunity and concomitantly control tumor growth in syngeneic mouse models [151].

3.3 The gut microbiome and hematological malignancies: a focus on hematopoietic stem cell transplantation and related complications

As discussed above, most studies on the role of GM in influencing therapies have focused on solid tumors, particularly melanoma. In parallel, another popular line of research has dealt with profiling the GM of patients suffering from hematological neoplasms (e.g., acute leukemia, lymphoma, and myeloma), with particular regard to the patients' clinical outcomes during and after ~~the~~ chemo-immunotherapeutic treatment. For patients with various blood tumors, first-line and

12

life-saving therapy is considered HSCT, a combination of stem cell therapy, conventional treatments (*i.e.*, chemotherapy and radiation) and immune therapy [152]. Unfortunately, HSCT can lead to life-threating complications, such as graft-versus-host disease (GvHD, *i.e.,* when alloreactive donor T cells attack host organs, such as skin, liver and gut), and local and systemic infections, and ~~tumor~~ cancer may relapse~~s may occur~~ [153]. In this context, recent studies in mice and humans suggest important links between GM and clinical outcomes, as well as a role of GM in immunological reconstruction in HSCT recipients [154-156]. Indeed, HSCT practices significantly affect GM balance with a reduction in diversity and sometimes monodominance by Proteobacteria members, *Enterococcus* or *Streptococcus* [157]. In a retrospective study, the reduction of GM diversity in patients undergoing HSCT was associated with a significant increase in mortality (*i.e.*, 52%) compared to patients with a high-diversity GM profile (*i.e.*, 8%) [158]. In addition, during the post-transplant period, antimicrobial treatments are commonly used to treat febrile neutropenia with the ultimate consequence of affecting the GM structure, which can result in increased susceptibility to bacterial infections [159]. For example, an increase in the level of *Enterococcus* spp. after antibiotic exposure correlated with an increased risk of developing bacteremia [157]. Similarly, enrichment of *Enterobacteriaceae* members and other Gram-negative microbes was associated with increased mortality [158]. Recent studies in animal models have shown that the development of GvHD is also associated with a peculiar GM dysbiosis, featured by increased levels of *Enterobacteriaceae* and a reduced amount of obligate anaerobes, mostly belonging to the Clostridiales order [160,161]. These findings were then confirmed in several clinical studies on both adult and pediatric patients [159, 162-165]. By reconstructing the GM dynamics across HSCT, some of these studies have suggested that the so-called "anti-inflammatory Clostridia", *i.e.*, members of the families *Clostridiaceae*, *Lachnospiraceae*, *Ruminococcaceae* and *Eubacteriaceae* (the main producers of SCFAs in the intestine), might exert a counteracting effect on GvHD onset and progression [166,167]. As further confirmation, a study on a large cohort of adults showed that the relative abundance of *Blautia*, a well-known health-associated SCFA-producing microorganism belonging to the *Lachnospiraceae* family [168], was correlated with reduced mortality from GvHD [169]. Increased proportions of *Blautia*, along with increased SCFA production, have recently been demonstrated in pediatric patients receiving post-transplant enteral rather than parenteral nutrition [170]. Interestingly, none of the enterally fed patients showed evidence of bloodstream infections, stressing the importance of maintaining a eubiotic GM configuration, capable of producing health-promoting metabolites, to reduce the risk of HSCT-related complications [170,171]. Bacterial-derived SCFAs, especially butyrate, have also been shown in a mouse model to improve the junctional integrity of intestinal epithelial cells, reduce apoptosis, and mitigate GvHD severity [166].

4. The big issue of the tumor microbiome

389 Since the work by Geller et al. [172] on pancreatic ductal adenocarcinoma, accumulating and robust evidence has

390 confirmed the existence of intratumoral microbes, which can act as intrinsic and essential components of the tumor

391 microenvironment, thus influencing cancer and cancer therapy. These microbes do not necessarily include only

392 "oncomicrobes", *i.e.*, microbes that are known to initiate cancer through genotoxin-mediated mutagenesis (such as

393 fragilisin- and reactive oxygen species-producing *B. fragilis* or colibactin-producing *E. coli*) [173,174] or by interfering

394 with important pathways involved in differentiation and morphogenesis (such as *F. nucleatum* expressing FadA that binds

395 to E-cadherin and activates Wnt-beta-catenin signaling) [175]. Indeed, it has recently emerged that many other

396 microorganisms may not be causative but rather complicit, acting mainly acting through the modulation of the host

397 immune system (immunosuppression or immunogenicity) or molecular mimicry [176].

398 To date, traces of bacterial DNA have been identified using next-generation sequencing approaches in at least 30 types

399 of cancer, including pancreatic, bile duct, lung, breast, ovarian, cervical, uterine, testicular, prostate, bladder, melanoma,

400 thyroid, kidney, leukemic, bone and brain cancers [177,178]. Notably, most major cancer types appeared to be featured

401 by unique microbial signatures, not only at the tissue level but also in the blood, thus paving the way for the use of plasma-

402 derived cell-free microbial DNA in novel microbiome-based diagnostic tools [178]. In particular, the ratio between taxa

403 belonging to the phylum Proteobacteria and those of Firmicutes varied in the different types of cancer, with the breast

404 cancer microbiome being the richest and most diverse of those analyzed to date [177]. Alongside the compositional traits,

405 it is worth noting that a tissue-specific enrichment of some bacterial functions has been hypothesized, which could be

406 related to the clinical features of the different tumor types [177]. For example, bacterial degradation of hydroxyproline,

407 deriving from bone collagen and particularly high in bone diseases, including cancer, was overrepresented in bone tumors.

408 Likewise, the pathways involved in the degradation of chemicals in cigarette smoke were enriched in lung cancer. While

409 these findings are expected, as they may be the result of host-driven or top-down selection, it should be pointed out that

410 they were generated through inferred metagenomics, with obvious interpretative limitations. The presence of microbial

411 components within some tumor tissues was also investigated by immunohistochemistry, which allowed to confirm that

412 not only nucleic acids but also structural components can be found, such as LPS from Gram-negative bacteria and

413 lipoteichoic acid from Gram-positive bacteria, can be found [177]. However, while LPS was frequently detected,

414 lipoteichoic acid was mainly found mainly in melanoma. These data were apparently in contrast to with those of

415 sequencingsequencing-derived ones, according to which many Gram-positive bacteria were represented in any tumor

416 type, but they may reflect an altered cell morphology (with lack of cell wall), as also hypothesized based on transmission

417 electron microscopy imaging and previous literature [179]. Based on the staining patterns, intratumor bacteria were mostly

418 localized in the cytoplasm and nucleus of cancer cells, as well as in immune cells, *i.e.*, in leukocytes and especially in

419 macrophages [177]. As for their number, in pancreatic ductal adenocarcinomas, an average of one bacterium per about

14

150 human cells has been estimated [172]. According to tumor mapping by Nejman et al. [177], the percentage of tumors positive for bacterial DNA ranged ~~between~~ from 14.3% in melanoma to >60% in breast, pancreatic and bone tumors. Based on these estimates, Sepich-Poore et al. [176] ~~came to the conclusion of~~concluded about 10^5 to 10^6 bacteria per palpable 1-cm^3 tumor, or about 34 bacteria per mm^2. The source of these microorganisms/microbial components is not yet clear, but they could likely be part of other host-associated ecosystems, such as GM, translocate ~~through~~ across compromised mucosal barriers (e.g., leaky gut), and then reach tumor masses, facilitated by their disorganized and leaky vasculature. For example, this has been strongly suggested for CRC liver metastases, where >99.9% nucleotide identity was found for *Fusobacterium* isolates from the primary tumor and metastatic site, although tissue collection occurred months if not years later [81]. Once in the bloodstream, *F. nucleatum* has been hypothesized to translocate also ~~to~~ in breast cancers, colonization of which is made possible by the binding of its lectin Fap2 to galactose and N-acetyl-d-galactosamine residues, abundantly expressed on cancer cells [180]. Obviously, work ~~is~~ still ~~needed~~ needs to be done to confirm all of these findings, including the dead/alive issue. Similarly, ~~it will have to be determined~~ whether these bacteria are actually involved in tumor pathogenesis or are mere opportunistic residents/passengers, which take advantage of a nutrient-rich and immunosuppressed environment, should be determined. Regardless, they may play a critical role in promoting tumor growth and/or mediating chemoresistance, thus affecting patient response and survival. This has been seen for example for Gammaproteobacteria that can inactivate the chemotherapeutic drug gemcitabine, ~~by~~ through the expression of a long isoform of the bacterial enzyme cytidine deaminase [172], and for *F. nucleatum*, which activates the autophagy pathway (by targeting TLR4 and MYD88 innate immune signaling and specific microRNAs), thus preventing chemotherapy-induced apoptosis [181]. *F. nucleatum* may also accelerate tumor growth by inducing apoptosis in lymphocytes, as suggested by the reduced levels of CD4+ and CD8+ T cells in breast cancers [180]. Notably, the administration of antibiotics (*i.e.*, metronidazole) inhibited *F. nucleatum*-induced tumor enlargement, stressing once again how microbial manipulation can have significant repercussions on clinical outcomes. Finally, it is worth mentioning that greater intratumoral diversity has been correlated with long-term survival in patients with pancreatic adenocarcinoma [182]. Long-term survivors also showed potentially favorable intratumoral microbial signatures (*i.e.*, *Saccharopolyspora*, *Pseudoxanthomonas*, *Streptomyces* and *Bacillus clausii*), which could promote the recruitment and activation of CD8+ T cells, with overproduction of interferon (IFN)-gamma, thus contributing to the antitumor immune response and influencing the natural history of the disease. Although the data are still preliminary, using FMT from long-term survivors with no evidence of disease in tumor-bearing mice, the authors observed immune system activation and antitumor response, thus opening the way to immense microbiome-based therapeutic opportunities. What is certain is, therefore, that future therapeutic strategies ~~can~~ will no longer be able to ignore the presence of intratumoral microbes, rather they

450 could be improved through integration with precision microbiome manipulation tools, targeting microbes and/or the
451 mechanisms in which they are involved.
452
453 **5. Modulation hypothesis: prebiotics, probiotics, live biotherapeutics and FMT, as adjuvant cancer therapy**
454 In recent times, enormous strides have been made in improving anticancer therapies, expanding the plethora of treatments
455 available and significantly reducing side effects, while paying attention to patient compliance [183]. As discussed above,
456 multiple lines of evidence have placed an increasing emphasis on how microbiome modulation may represent be a crucial
457 adjunct to current anticancer therapies [141,184-186]. Microbiome-tailored precision medicine is based on the use of
458 prebiotics, (traditional and next-generation) probiotics and FMT, to be personalized for the best efficacy and safety
459 according to the patient's microbiome configuration and other host metadata, for the best efficacy and safety. Herein, we
460 will discuss the most recent and relevant clinical trials that have been planned (some still ongoing) to shed light on the
461 therapeutic potential of GM manipulation in cancer patients (using the tools mentioned above), in terms of improved
462 response and mitigation of adverse events. See **Table 1** for a summary of the clinical trials that have been registered in
463 the last two years.
464
465 *5.1 Prebiotics*
466 Prebiotics are typically referred to as "a substrate that is selectively utilized by host microorganisms conferring a health
467 benefit" [187]. In particular, they exert their beneficial effects by promoting the expansion and/or metabolic activity of
468 specific groups of commensals, including keystone taxa. Other induced effects at the microbial ecosystem level include
469 growth promotion through cross-feeding interactions and inhibitory effects against pathogens or pathobionts, through
470 displacement, production of antimicrobial metabolites or other changes in microbial fitness [185,188,189]. Evidences
471 gathered from in *in vitro* and *in vivo* studies suggestss that administering prebiotics is a promising and safe therapeutic
472 strategy in different clinical settings [151,185]. A recent study has also demonstrated that discrete dietary fiber structures
473 (*i.e.*, chemically modified resistant starches with small structural differences) are able to induce divergent and highly
474 specific effects on GM, which directly changess in SCFA production, thus paving the way for precision manipulation of
475 the GM through *ad hoc* designed carbohydrates [190]. With specific regard to cancer, however, only a limited number of
476 interventional studies in humans are available to date, with sometimes conflicting results. For example, oral consumption
477 of amylase-resistant starch as a prebiotic formulation, administered in combination with chemotherapy, was not
478 conclusive in the prevention of acute radiation proctitis in patients with cervical cancer [191]. Conversely, a prebiotic
479 regimen based on fructooligosaccharides, xylooligosaccharides, polydextrose, and resistant dextrin, administered 7 days
480 prior to surgery for CRC surgery, improved serum immunological markers, reversing the surgical stress-induced surge of

16

opportunistic pathogens in GM [192]. The interventional clinical trial conducted by Garcia-Peris and colleagues ([193]; NCT01549782) on 40 women undergoing radiotherapy for endometrial neoplasms confirmed the hypothesis that a mixture of fructooligosaccharides and inulin modulates the representation of *Lactobacillus* and *Bifidobacterium* within the GM community, while reducing tissue damage at the enterocyte level. As briefly mentioned above, in a mouse melanoma model, inulin and mucin also stimulated *Bifidobacterium* spp. and *A. muciniphila* [151], both previously identified as beneficial GM components, capable of eliciting effective antitumor immunity [140,146]. Regarding clinical trials in cancer patients still ongoing and started in the last two years (**Table 1**), one study foresees the enrolment of 120 participants with gastrointestinal cancer and chemotherapy-related diarrhea (NCT04447443) and focuses on a 2-week supplementation with prebiotic fiber ~~supplement~~ along with loperamide hydrochloride ~~administration~~. Longitudinal monitoring of the GM configuration and subsequent comparison with the results obtained from the administration of placebo (*i.e.*, maltodextrin) and loperamide will allow researchers to dissect the effects specifically induced by prebiotics. A second study (NCT04624568) aims to compare the regression rate of cervical intraepithelial lesions in 150 women after 6-month administration of a vaginal gel composed of hyaluronic acid and prebiotic extract of *Coriolus versicolor*, which improves the re-epithelialization of the uterine cervix [194]. Creating a protective biofilm on the cervix would help restore a niche environment conducive to regression of intraepithelial lesions and human papillomavirus clearance. Although the aforementioned studies are still in their infancy, they have the potential to provide valuable insights into how prebiotic administration modulates the microbiome of cancer patients, while influencing disease markers and clinical outcomes.

5.2 Probiotics and live biotherapeutics

Probiotics, defined as "live microorganisms that, when administered in adequate amounts, confer a health benefit to the host" [195], are a GM manipulation tool with a long history of use. Those currently most used and studied are certainly bifidobacteria and lactobacilli, but also, to a lesser extent, strains of *Lactococcus* spp., *Streptococcus thermophilus*, *Saccharomyces boulardii* and *E. coli* Nissle 1917. Clinical efficacy, mechanisms of action and caveats in the field are admirably discussed elsewhere (see for example Suez et al.~~,~~ [196]). In the context of cancer patients, strains of *Lactobacillus* and *Bifidobacterium* have stood out for their ability to delay tumor formation, inhibit tumor cell proliferation and prevent life-threatening side effects associated with chemotherapy treatments, in addition to ~~the~~ binding and degradation of carcinogenic compounds, ~~the~~ inhibition of carcinogen-producing enzymes, and immunomodulating and anti-inflammatory properties [197-201]. It is also worth noting that probiotic strains of *Bifidobacterium* and *Clostridium*, when administered intravenously, have been shown to colonize hypoxic tumors, preferably thriving in solid malignancies [202]. However, despite the encouraging results, most probiotic therapies in oncology are still in the preclinical stage and very few studies have ~~have~~ reported the effects of probiotics in humans [201,203] (see also **Table**

17

512   **1**). Among them, a clinical trial in CRC patients showed that probiotic (*Bifidobacterium lactis* Bl-04 and *L. acidophilus*

513   NCFM) administration promoted the expansion of beneficial butyrate-producing microbes in both mucosa and feces, and

514   tended to reduce *Fusobacterium* proportions (NCT03072641; Hibberd et al., [204]). Furthermore, preoperative probiotic

515   (*S. boulardii*) therapy resulted in reduced levels of IL-1beta, IL-10, and IL-23 mRNA within the colonic mucosa of CRC

516   patients following resection, when compared to controls who received the anticancer treatment alone (NCT01895530)

517   [205]. As for other cancer types, improved relapse-free survival was observed after administering an oral preparation of

518   *L. casei* for one year to patients with superficial bladder cancer, after completion of transurethral resection therapy

519   followed by intravesical administration of epirubicin, although no difference in overall survival was observed compared

520   to the control group [206]. Beneficial effects on GM are also expected in an ongoing clinical trial, which involves a short

521   course of probiotic therapy (with the following 13 species: *S. boulardii*, *Lactobacillus plantarum*, *Bacillus subtilis*, *B.*

522   *lactis*, *Bifidobacterium bifidum*, *Lactobacillus rhamnosus*, *B. breve*, *L. casei*, *Lactobacillus salivarius*, *L. acidophilus*,

523   *Lactobacillus brevis*, *B. longum* and *Lactobacillus paracasei*) in patients with operable breast cancer before surgery

524   (NCT03358511). Interestingly, variations within the tumor microenvironment are also expected, with in particular an

525   increase in the resident CD8+ T cell subpopulation. In another clinical trial, ~~the~~ researchers aim to evaluate the efficacy

526   of the probiotics administered (no information is available on the strains or species used) prior to surgery in 40 patients

527   with breast and lung cancer, while assessing systemic and intratumoral immunomodulatory effects (NCT04857697). The

528   enrollment of 40 patients with potential/resectable non-small cell lung cancer is instead planned to evaluate the safety and

529   effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics (again, no compositional information

530   is available) (NCT04699721). Within the Thoracic POISE project [207], the efficacy of a probiotic blend of *Lactobacillus*

531   and *Bifidobacterium* spp. (*i.e.*, Pro 12) will be assessed in reducing surgical adverse events, prolonging overall survival

532   and pioneering integrative care delivery in 40 patients with esophageal cancer (NCT04871412).

533   As next-generation probiotics, live biotherapeutics, defined as "live organisms designed and developed to treat, cure, or

534   prevent a disease or condition in humans" [208], have the potential to ~~represent~~ be a decisive tool for the improvement of

535   current anticancer therapies [209]. This category encompasses GM members that have emerged thanks to advances in

536   massive sequencing technologies but also engineered microbes, *i.e.*, GRAS (generally recognized as safe) organisms or

537   commensals, which are used as a delivery vehicle for a bioactive molecule or to express certain functionalities [210]. The

538   former includes, for example, *A. muciniphila* (identified as a predictor of response in melanoma) [140], as well as

539   *Bacteroides ovatus* and *Bacteroides xylanisolvens*, both of which have been associated with enhanced cancer immune

540   surveillance [211,212]. As for recombinant bacterial therapeutics, although they are currently being tested in clinical

541   trials, none of them have so far been approved for use in humans. Among these, *B. longum* expressing the pro-

542   inflammatory IL-12 transgene (bacTRL-IL-12) was selected to evaluate the beneficial effects on solid tumors, in terms

of stimulation of the local and systemic anticancer immune response (phase I, Symvivo). The clinical trial focusing on the safety, tolerability and preliminary evaluation of the anticancer efficacy of bacTRL-IL-12 following intravenous infusion was recently conducted on 5 participants (NCT04025307). *E. coli* Nissle 1917, engineered to produce cyclic adenosine diphosphate, a stimulator of the STING (STimulator of INterferon Genes) pathway (SYNB1891; phase I Synlogic), has also been identified as a promising live biotherapeutic agent for the adjuvant treatment of solid tumors but, to date, clinical trials are still ongoing. In particular, the study NCT04167137 involves intratumoral injection of SYNB1891 in patients with diagnosed advanced/metastatic solid tumors and lymphomas, undergoing imaging to assess tumor response and safety monitoring. After determination of dose-limiting toxicity, SYNB1891 will be administered in combination with immunotherapy treatment (*i.e.*, atezolizumab). It is worth noting that *E. coli* Nissle 1917 has also been engineered to bind to the surface of CRC cells and secrete myrosinase, an enzyme capable of converting glucosinolates in cruciferous plants into isothiocyanates such as sulforaphane, a small molecule with known anticancer activities [213]. In murine models of CRC, fed with engineered microbes and a cruciferous vegetable diet, the authors observed significant tumor regression and reduced tumor recurrence. Finally, a double-blind, randomized interventional study on 100 women with breast cancer has been planned to evaluate the effect of an investigational product (a probiotic from BIOHM Health LLC, engineered to address the key role of fungi in digestive health) administered in combination with standard anticancer therapy, on the breast cancer microbiome and GM (NCT04362826).

On the other side of the coin, some studies have shown deleterious effects for probiotics in cancer patients, even using the same strains, such as an increase in tumor penetrance and multiplicity [214]. Discordant and heterogeneous evidence of efficacy strongly underscores the need for a precision tailored approach, which ~~takes into account~~considers the individual microbiome configuration (in terms of composition and functionality), host metadata (e.g., genetics, anthropometrics and immune profiling) and varying environmental exposures [196,215]. However, it remains undeniable that extreme caution should be taken when administering live microbes to individuals who are very often immunocompromised, due to primary disease and/or therapeutic treatments [196,216].

5.3 FMT

As already defined, FMT is the therapeutic procedure that involves the transfer of microbes from healthy individuals to recipients hosting a dysbiotic GM layout, with the aim of normalizing its structure and functionality towards an eubiotic state [186, 217-219]. Since 2018, increasing attention has been paid to the manipulation of GM through FMT in ~~the field of~~ oncology, with particular regard to immune checkpoint blockade [141,220]. From the perspective of microbiome-based medicine, FMT could be administered as a drastic tool for cancer patients who are unresponsive to therapies, to improve systemic and antitumor immune responses. As discussed above, in a pioneering study in an animal model ~~study~~, FMT

574 from non-responding cancer patients to tumor-bearing mice conferred the resistance phenotype to the recipient, while

575 infusions from responding patients restored reactivity to PD-1 blockade [140]. Subsequently, clinical benefits were

576 obtained as a result of FMT in patients with immunotherapy-resistant metastatic melanoma. In particular, the

577 administration of anti-PD1 in combination with FMT, performed every 14 days for up to 90 days, induced objective or

578 complete responses in three out of five patients, crossing the 6-month progression-free survival landmark [221]. The shifts

579 induced in the GM composition after treatment included the expansion of bacterial species potentially favorable to

580 immunotherapy, *i.e.*, *Ruminococcus* spp. (*R. gnavus* and *R. callidus*) and *B. adolescentis*. In parallel, the tumor

581 microenviroment also underwent a reprogramming, consisting in an upregulation of the IFN-gamma-mediated signaling

582 pathway, together with effector T functions. In a second recent study on 16 patients with advanced melanoma, a single

583 FMT from seven different donors was administered in combination with PD-1 blockade [222]. PD-1 refractory patients

584 exhibited a shift towards donor GM composition, along with significant metabolic changes and reprogramming of the

585 tumor microenvironment, thereby overcoming primary resistance to immunotherapy. Taken together, these pivotal studies

586 led to the first proof of concept that FMT transfers clinical benefits to patients with immunotherapy-resistant metastatic

587 melanoma, by shifting their GM towards a donor-like profile associated with immune activation, mitigation of anti-

588 inflammatory tone and modification of host metabolism.

589 Among the clinical trials on FMT in cancer patients, registered in the past two years and currently underway (**Table 1**),

590 only two studies are in the active recruitment phase. The first trial (NCT04721041) involves the enrollment of 40

591 participants and focuses on the treatment of oncotherapy-related intestinal complications by evaluating the efficacy of

592 washed microbiota transplantation (WMT), a new stage of FMT. Consisting of sequential microfiltration and

593 centrifugation steps, WMT has been shown to reduce the rate of adverse events potentially associated with classic

594 microbiome-based treatment (e.g., fever, diarrhea, abdominal pain, nausea and vomiting), without compromising the

595 effectiveness of the procedure [223,224]. The second randomized controlled clinical trial (NCT04758507) aims to

596 evaluate the efficacy of FMT in improving response rates to immune checkpoint inhibitors in 50 patients with advanced

597 renal cell carcinoma, by selecting donors who respond to therapy. Recipient patients will receive the first infusion by via

598 colonoscopy, while frozen fecal capsules at three and six months after the first treatment. Four of the remaining five

599 clinical trials listed in **Table 1** concern the evaluation of the safety and efficacy of FMT, as well as the enhancement of

600 immunotherapy treatment in 20 patients with advanced lung cancer (NCT04924374), 15 participants with metastatic CRC

601 (NCT04729322), 50 patients with metastatic or inoperable melanoma or non-small cell lung cancer (NCT04521075), and

602 60 patients with malignant melanoma prior refractory to immune checkpoint inhibitors (NCT04577729). Finally, the

603 efficacy of FMT will be assessed in the prevention of allogenic HSCT complications, particularly GvHD, in a prospective

604 multi-center randomized phase II clinical trial on 150 participants (NCT04935684).

20

While it is proving to be a valid and promising tool for modulating GM, as expected, the safety of FMT is still debated, especially as large cohort studies on long-term safety are currently lacking [225]. The risk of adverse events potentially caused by FMT treatment suggests that great caution should be taken in choosing the most suitable microbiome-tailored treatment, especially in cancer patients already severely compromised by standard chemo-immunotherapy treatments.

6. Application of novel microbiome-based approaches in cancer medicine: machine learning as thea key for to patient stratification and outcome prediction

6.1 The promise of machine learning

As discussed in the previous paragraphs, research in recent decades has highlighted the dramatic impact of GM on multiple aspects of human pathophysiology, including the development and progression of cancer. This was possible thanks to 'omics' techniques (*i.e.*, 16S rRNA gene sequencing, shotgun metagenomics and metatranscriptomics, metaproteomics and metabolomics), which led to a paradigm shift in the field of microbiology, moving from the study of single microbial colonies to a high-resolution taxonomic and functional profiling of microbial communities. However, it is undeniable that we are still far from a full understanding of the terms of the GM-host interaction, a *sine qua non* for the development of truly effective preventive and intervention strategies. In parallel, enormous progresses has haves been made in the field of analytical approaches to data, whose collection, organization and mining are fundamental steps for the analysis of complex interaction networks. Overall, technological advances in molecular biology and computer science are driving medical science towards big data. This large amount of data can potentially be explored via artificial intelligence methods, such as machine learning (ML) approaches that can handle large-scale datasets. ML is a data-driven approach capable of mining complex data, discovering informative patterns. In a nutshell, ML identifies algorithms capable of learning patterns from data in a self-manner, which enables the machine to solve a specific task, and deal with invisible data without explicit programming. In principle, the more heterogeneous data are used to train the model, the better the algorithm can generalize the problem when dealing with new data. Within ML, deep learning algorithms can better handle complex, multi-modal data. The premise of the emergence of ML techniques in various scientific fields, including healthcare, is the possibility of automating certain repetitive tasks, with the aim of achieving greater accuracy than that achievable by human experts, with also the possibility of estimating and predicting parameters, such as health risk factors. ML methods can adopt and combine different sources of health-related data, leveraging the tasks of diagnosing, prognosis, disease risk and potential treatments, with the aim of progressing towards a treatment tailored to the patient profile. ML algorithms can be supervised, *i.e.*, we know *a priori*, based on manual curation, how the samples are tagged. Supervised techniques are adopted to answer specific problems, by training the algorithm to recognize distinct features of the dataset. Halfway between supervised and unsupervised learning, semi-supervised learning can be applied

when we have incompletely labelled datasets, as it can be a real-word scenario [226]. With unsupervised algorithms, common features from input data are extracted, for instance, by grouping the samples based on the metagenomic profile. Unsupervised tasks are implemented through clustering (e.g., k-means, hierarchical) and dimensionality reduction algorithms, helping to explore and visualize similarities between samples. Overall, non-linear dimensionality reduction approaches (PCoA, UMAP), and autoencoders are adopted for microbial data, as these techniques are suitable for handling sparse data. Different types of algorithms can be used both for ~~both~~ classifications, identifying a sample as healthy or diseased based on the metagenomics profile, and for regression, for instance determining what the expression value would be for a given bacterial species upon treatment. Furthermore, ensemble strategies combine multiple models~~, to obtain~~ for more robust and accurate results. When building a new model, the crucial steps are training and testing the model. To validate its performance, the dataset on which the model is trained is divided into training and testing subsets. The more data we can start with, the higher ~~the are~~ the chances that the algorithm can be better trained. The training set will be used to train the model, while the testing set must be a dataset not previously seen by the model during the training phase, in order to evaluate retrospectively and in an unbiased manner its performance. Shortcomings related to the model performance include overfitting, when the model is well trained on the dataset used for training, leading to high accuracy when applied to test data from the same dataset, but poor results when dealing with new datasets (*i.e.*, the model has little power to generalize the problem). On the other hand, the model may be underfitted to the data and not be able to generate predictions with sufficient accuracy even on the testing dataset. Very important components of model training in supervised tasks are the dataset annotation and the degree of curation of the data. In this regard, a certain level of expertise on the data based on the application task and data type, would be another important component of the ML workflow. The performance of a~~n~~ ML model is also subject to the computational power at disposal, which plays an important role in model training, especially when dealing with deep learning models. Furthermore, reproducibility, pipeline standardization and data accessibility are other major challenges. All this is even more true in the field of GM, whose complexity and high inter-individual and temporal variability stress the need for standards and cross-study validation of models. In this regard, the COST Action CA18131 "ML4Microbiome" project aims to tackle the issues related to the advent of ML in the microbiome field [227].

6.2 Machine learning in clinical oncology practice

Following the trend of increasing data collection, ML algorithms have been successfully applied to various problems, predicting human faces, targeting consumer behaviors, and also in relation to protein structure and function [228], drug discovery [229], and cancer detection [230]. ML models and algorithms are highly flexible between different scientific fields. However, data filtering and preparation require some knowledge. In oncology, ML approaches have already some

22

applications. Just to name a few based on imaging data, ML models have been used for breast density assessment [231], and for the detection of malignant lung nodules [232]. Furthermore, CURATE.AI is an artificial intelligence platform that has been trained on prostate cancer patient's health records and used by doctors to choose the optimal dose of drugs [233]. While for model training on imaging data, the detection accuracy is comparable to that of radiologists, or in some cases even better performing, ML models based on health records still need further evaluation. In any case, the model results require a review by the physician, as in some cases they may go against clinical guidelines. One major limitation is the inability to benchmark these tools towards a larger real-world dataset. In order to deploy ML tools in real clinical practice, several aspects must be taken into consideration and continuous and extensive collaboration between clinicians and informaticians is required, as well as data curation and longitudinal studies to monitor clinical outcomes [234].

6.3 Machine learning application in oncology with omics data

Nowadays, the boost of microbiome studies in the microbiome field and the availability of large datasets in public repositories are enabling the application of ML to metagenomics, which could lead to the identification of microbial species or other biomarkers, such as genes/enzymes and metabolites, for cancer diagnosis and prognosis [235]. Microbiome data combined with patient genetic information, but also with other types of omics data (transcriptomics, proteomics, metabolomics), could therefore return a comprehensive picture of the biological complexity of the disease and play a leading role in defining a personalized medicine approach. For example, predictions over microbiome-drug interactions could be the key to guiding precision therapeutic solutions. Recently, metagenomic data from CRC patients and healthy subjects have beenwere used to train a random forest classifier [236]. The model identified six key microbial species, *i.e.*, *Porphyromonas asaccharolytica*, *Peptostreptococcus stomatis*, *Fusobacterium* spp., *Parvimonas* spp., *Streptococcus vestibularis* and *Flavonifractor plautii*, which discriminated between controls and patients. Another work based on a random forest classifier and CRC, was trained on the metagenomic and metabolomics data from an Indian cohort of 30 patients and 30 healthy subjects. This work identified *F. plautii* as a cancer biomarker, and also found discriminating microbial genes for CRC. Interestingly, the authors hypothesized that flavonoid degradation by *Flavonifractor* is a key component for cancer progression [237]. More recently, Jang et al. [238] applied a Bayesian network model to find out species signatures in patients responding to chemotherapy treatment, while Kharrat et al. [239] adopted an ensemble method, including a Bayesian network model, to identify CRC-related microbial species. We would also like to mention the recently established Gut OncoMicrobiome Signatures project, which aims to identify microbial signatures of cancer progression and response to therapy [235]. These applications have defined or aim to define marker microbial species that could help better stratify patients, as well as guide GM remodeling via microbiome-based strategies, as outlined above. In this regard, ML could be used to screen large datasets in order to find potential new probiotics,

698 which will then have to be experimentally validated, or novel compounds to be evaluated for their therapeutic potential,

699 as well as to refine/personalize drug therapies. A rRecent work [240] based on unsupervised ML techniques, has identified

700 structural similarities between drugs that can be metabolized by bacteria, with important implications in pharmacological

701 research. For example, it has been shown that chemical groups such as the amide and ester groups can be hydrolyzed by

702 Bacteroidetes members. A similar application led to the implementation of the Drugbug database, a resource that collects

703 data on the bacterial metabolism of drugs. These data were used to train a random forest model that allowed for the

704 classification of compounds based on microbial metabolism [241]. By exploiting different types of omics data (from

705 metagenomics to metabolomics), ML approaches could therefore help to delineate microbiome-drug interactions, with

706 the possibility of predicting drug response and related toxicity. On the other hand, it should be remembered that certain

707 drugs, other than antibiotics, can shape the GM structure, eventually leading to a dysbiotic state. New studies are

708 investigating this aspect [240,242,243].

709 In summary, ML can set the direction of personalized precision medicine, helping to overcome the barrier of huge volume

710 of data analysis, with the ability to perform classification and prediction tasks. ML can be adopted to stratify patients

711 based on individual characteristics, including microbiome profile, and predict clinical outcomes (including response to

712 therapy), as well as identify novel health- or disease-promoting taxa/compounds, determine microbiome-drug interactions

713 and therefore guide the design of microbiome-targeted strategies to prevent/fight cancer, ensuring a long-term positive

714 response. ML methods applied to the microbiome/cancer fields offer a valuable bench-free way to sift through possible

715 solutions, which will then need to be validated by experimenters and clinicians. To speed up research in this field,

716 collaborations between among the clinical, biotechnological and bioinformatic parties for data model evaluation and

717 results interpretation will be mandatory.

718

719 **7. Conclusions and perspectives**

720 The gut microbiome has recently taken a leading role in research focused on maintaining the physiological wellbeing of

721 the host. On the other hand, evidence of a direct relationship between certain microbes and cancer development, as well

722 as the recent involvement of microbiomes in the outcomes of anticancer therapy, have left the door open to a new frontier

723 in microbiome-based research in these fields. In this scenario, the introduction of multi-omics approaches and novel

724 bioinformatic tools are helping to understand the role of microbial ecosystems in these unimaginableed lapels of the

725 relationship with the host. However, there are still few studies in large cohorts and many knowledge gaps to be filled,

726 especially in terms of underlying mechanisms and the development of safe and effective intervention strategies. Only

727 through transdisciplinary collaborations, it will be possible to move forward with the development of personalized

728 microbiome-based interventions, to overcome resistance to anticancer treatments and reduce the risk of relapse.

729

Consent for Publication

Not applicable.

25

References

1. Gilbert, J.A.; Blaser, M.J.; Caporaso, J.G.; Jansson, J.K.; Lynch, S.V.; Knight, R. Current understanding of the human microbiome. *Nat. Med.,* **2018**, *24*, 392-400.

2. Turnbaugh, P.J.; Ley, R.E.; Hamady, M.; Fraser-Liggett, C.M.; Knight, R.; Gordon, J.I. The human microbiome project. *Nature*, **2007**, *449*, 804-810.

3. Lynch, S.V.; Pedersen, O. The human intestinal microbiome in health and disease. *N. Engl. J. Med.*, **2016**, *375*, 2369-2379.

4. Oh, C.M.; Lee, D.; Kong, H.J.; Lee, S.; Won, Y.J.; Jung, K.W.; Cho, H. Causes of death among cancer patients in the era of cancer survivorship in Korea: Attention to the suicide and cardiovascular mortality. *Cancer Med.*, **2020**, *9*, 1741-1752.

5. Farré-Maduella, E.; Casals-Pascual, C. The origins of gut microbiome research in Europe: From Escherich to Nissle. *Hum. Microbiome J.*, **2019**, *14*, 100065.

6. Escherich, T. Die Darmbakterien des Säuglings und ihre Beziehungen zur Physiologie der Verdauung, Stuttgart: Enke Verlag, **1886**.

7. Rajilić-Stojanović, M.; de Vos, V.M. The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol. Rev*., **2014**, *38*, 996-1047.

8. Savage, D.C. Microbial ecology of the gastrointestinal tract. *Annu. Rev. Microbiol.*, **1977**, *31*, 107-133.

9. Sender, R.; Fuchs, S.; Milo, R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol.,* **2016**, *14*, e1002533.

10. Neish, A.S. Microbes in gastrointestinal health and disease. *Gastroenterology*, **2009**, *136*, 65-80.

11. Gill, S.R.; Pop, M.; Deboy, R.T.; Eckburg, P.B.; Turnbaugh, P.J.; Samuel, B.S.; Gordon, J.I.; Relman, D.A.; Fraser-Liggett, C.M.; Nelson, K.E. Metagenomic analysis of the human distal gut microbiome. *Science*, **2006**, *312*, 1355-1359.

12. Candela, M.; Biagi, E.; Maccaferri, S.; Turroni, S.; Brigidi P. Intestinal microbiota is a plastic factor responding to environmental changes. *Trends Microbiol*., **2012**, *20*, 385-391.

13. Robertson, R.C.; Manges, A.R.; Finlay, B.B.; Prendergast, A.J. The human microbiome and child growth - first 1000 days and beyond. *Trends Microbiol.*, **2019**, *27*, 131-147.

14. Derrien, M.; Alvarez, A.S.; de Vos, W.M. The gut microbiota in the first decade of life. *Trends Microbiol*., 2019, *27*, 997-1010.

15. Bäckhed, F.; Roswall, J.; Peng, Y.; Feng, Q.; Jia, H.; Kovatcheva-Datchary, P.; Li, Y.; Xia, Y.; Xie, H.; Zhong, H.; Khan, M.T.; Zhang, J.; Li, J.; Xiao, L.; Al-Aama, J.; Zhang, D.; Lee, Y.S.; Kotowska, D.; Colding, C.;

772   Tremaroli, V.; Yin, Y.; Bergman, S.; Xu, X.; Madsen, L.; Kristiansen, K.; Dahlgren, J.; Wang, J. Dynamics and
773   stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe,* **2015**, *17*, 690-703.

774 16. Avershina, E.; Lundgård, K.; Sekelja, M.; Dotterud, C.; Storrø, O.; Øien, T.; Johnsen, R.; Rudi, K. Transition
775   from infant- to adult-like gut microbiota. *Environ. Microbiol.,* **2016**, *18*, 2226-2236.

776 17. Pannaraj, P.S.; Li, F.; Cerini, C.; Bender, J.M.; Yang, S.; Rollie, A.; Adisetiyo, H.; Zabih, S.; Lincez, P.J.;
777   Bittinger, K.; Bailey, A.; Bushman, F.D.; Sleasman, J.W.; Aldrovandi, G.M. Association between breast milk
778   bacterial communities and establishment and development of the infant gut microbiome. *JAMA Pediatr.,* **2017**,
779   *171*, 647-654.

780 18. Vangay, P.; Ward, T.; Gerber, J.S.; Knights, D. Antibiotics, pediatric dysbiosis, and disease. *Cell Host Microbe*,
781   **2015**, *17*, 553-564.

782 19. Rooks, M.G.; Garrett, W.S. Gut microbiota, metabolites and host immunity. *Nat. Rev. Immunol*., **2016**, *16*, 341-
783   352.

784 20. Macpherson, A.J.; de Agüero, M.G.; Ganal-Vonarburg, S.C. How nutrition and the maternal microbiota shape
785   the neonatal immune system. *Nat. Rev. Immunol*., **2017**, *17*, 508-517.

786 21. Olszak, T.; An, D.; Zeissig, S.; Vera, M.P.; Richter, J.; Franke, A.; Glickman, J.N.; Siebert, R.; Baron, R.M.;
787   Kasper, D.L.; Blumberg, R.S. Microbial exposure during early life has persistent effects on natural killer T cell
788   function. *Science*, **2012**, *336*, 489-493.

789 22. Cox, L.M.; Yamanishi, S.; Sohn, J.; Alekseyenko, A.V.; Leung, J.M.; Cho, I.; Kim, S.G.; Li, H.; Gao, Z.;
790   Mahana, D.; Zárate Rodriguez, J.G.; Rogers, A.B.; Robine, N.; Loke, P.; Blaser, M.J. Altering the intestinal
791   microbiota during a critical developmental window has lasting metabolic consequences. *Cell*, **2014**, *158*, 705-
792   721.

793 23. Vatanen, T.; Franzosa, E.A.; Schwager, R.; Tripathi, S.; Arthur, T.D.; Vehik, K.; Lernmark, Å.; Hagopian, W.A.;
794   Rewers, M.J.; She, J.X.; Toppari, J.; Ziegler, A.G.; Akolkar, B.; Krischer, J.P.; Stewart, C.J.; Ajami, N.J.;
795   Petrosino, J.F.; Gevers, D.; Lähdesmäki, H.; Vlamakis, H.; Huttenhower, C.; Xavier, R.J. The human gut
796   microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature*, **2018**, *562*, 589-594.

797 24. Chua, H.H.; Chou, H.C.; Tung, Y.L.; Chiang, B.L.; Liao, C.C.; Liu, H.H.; Ni, Y.H. Intestinal dysbiosis featuring
798   abundance of *Ruminococcus gnavus* associates with allergic diseases in infants. *Gastroenterology*, **2018**, *154*,
799   154-167.

800 25. Maruvada, P.; Leone, V.; Kaplan, L.M.; Chang, E.B. The human microbiome and obesity: moving beyond
801   associations. *Cell Host Microbe*, **2017**, *22*, 589-599.

802 26. Stewart, C.J.; Ajami, N.J.; O'Brien, J.L.; Hutchinson, D.S.; Smith, D.P.; Wong, M.C.; Ross, M.C.; Lloyd, R.E.;
803   Doddapaneni, H.; Metcalf, G.A.; Muzny, D.; Gibbs, R.A.; Vatanen, T.; Huttenhower, C.; Xavier, R.J.; Rewers,
804   M.; Hagopian, W.; Toppari, J.; Ziegler, A.G.; She, J.X.; Akolkar, B.; Lernmark, A.; Hyoty, H.; Vehik, K.;
805   Krischer, J.P., Petrosino, J.F. Temporal development of the gut microbiome in early childhood from the TEDDY
806   study. *Nature*, **2018**, *562*, 583-588.

807 27. He, Y.; Wu, W.; Zheng, H.M.; Li, P.; McDonald, D.; Sheng, H.F.; Chen, M.X.; Chen, Z.H.; Ji, G.Y.; Zheng,
808   Z.D.; Mujagond, P.; Chen, X.J.; Rong, Z.H.; Chen, P.; Lyu, L.Y.; Wang, X.; Wu, C.B.; Yu, N.; Xu, Y.J.; Yin,
809   J.; Raes, J.; Knight, R.; Ma, W.J.; Zhou, H.W. Regional variation limits applications of healthy gut microbiome
810   reference ranges and disease models. *Nat. Med.*, **2018**, *24*, 1532-1535.

811 28. Rothschild, D.; Weissbrod, O.; Barkan, E.; Kurilshikov, A.; Korem, T.; Zeevi, D.; Costea, P.I.; Godneva, A.;
812   Kalka, I.N.; Bar, N.; Shilo, S.; Lador, D.; Vila, A.V.; Zmora, N.; Pevsner-Fischer, M.; Israeli, D.; Kosower, N.;
813   Malka, G.; Wolf, B.C.; Avnit-Sagi, T.; Lotan-Pompan, M.; Weinberger, A.; Halpern, Z.; Carmi, S.; Fu, J.;
814   Wijmenga, C.; Zhernakova, A.; Elinav, E.; Segal, E. Environment dominates over host genetics in shaping
815   human gut microbiota. *Nature*, **2018**, *555*, 210-215.

816 29. Wild, C.P. Complementing the genome with an "exposome": the outstanding challenge of environmental
817   exposure measurement in molecular epidemiology. *Cancer Epidemiol. Biomarkers Prev.*, **2005**, *14*, 1847-1850.

818 30. Fassarella, M.; Blaak, E.E.; Penders, J.; Nauta, A.; Smidt, H.; Zoetendal, E.G. Gut microbiome stability and
819   resilience: elucidating the response to perturbations in order to modulate gut health. *Gut*, **2021**, *70*, 595-605.

820 31. Iacob, S.; Iacob, D.G.; Luminos, L.M. Intestinal microbiota as a host defense mechanism to infectious threats.
821   *Front. Microbiol.*, **2018**, *9*, 3328.

822 32. Thaiss, C.A.; Zmora, N.; Levy, M.; Elinav, E. The microbiome and innate immunity. *Nature*, **2016**, *535*, 65-74.

823 33. Turroni, S.; Brigidi, P.; Cavalli, A.; Candela, M. Microbiota-host transgenomic metabolism, bioactive molecules
824   from the Inside. *J. Med. Chem.*, **2018**, *61*, 47-61.

825 34. Sonnenburg, E.D.; Sonnenburg, J.L. Starving our microbial self: the deleterious consequences of a diet deficient
826   in microbiota-accessible carbohydrates. *Cell Metab.,* **2014**, *20*, 779-786.

827 35. Koh, A.; De Vadder, F.; Kovatcheva-Datchary, P.; Bäckhed, F. From dietary fiber to host physiology: Short-
828   chain fatty acids as key bacterial metabolites. *Cell*, **2016**, *165*, 1332-1345.

829 36. Desai, M.S.; Seekatz, A.M.; Koropatkin, N.M.; Kamada, N.; Hickey, C.A.; Wolter, M.; Pudlo, N.A.; Kitamoto,
830   S.; Terrapon, N.; Muller, A.; Young, V.B.; Henrissat, B.; Wilmes, P.; Stappenbeck, T.S.; Núñez, G.; Martens,
831   E.C. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen
832   susceptibility. *Cell*, **2016**, *167*, 1339-1353.

833   37. Oh, J.H.; Alexander, L.M.; Pan, M.; Schueler, K.L.; Keller, M.P.; Attie, A.D.; Walter, J.; van Pijkeren, J.P.
834   Dietary fructose and microbiota-derived short-chain fatty acids promote bacteriophage production in the gut
835   symbiont *Lactobacillus reuteri*. *Cell Host Microbe*, **2019**, *25*, 273-284.

836   38. Davie, J.R. Inhibition of histone deacetylase activity by butyrate. *J. Nutr.*, **2003**, *133*, 2485S-2493S.

837   39. Fukuda, S.; Toh, H.; Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping,
838   D.L.; Suzuki, T.; Taylor, T.D.; Itoh, K.; Kikuchi, J.; Morita, H.; Hattori, M.; Ohno, H. Bifidobacteria can protect
839   from enteropathogenic infection through production of acetate. *Nature*, **2011**, *469*, 543-547.

840   40. Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.;
841   Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J.; Pike, N.B.; Strum, J.C.; Steplewski, K.M.; Murdock, P.R.;
842   Holder, J.C.; Marshall, F.H.; Szekeres, P.G.; Wilson, S.; Ignar, D.M.; Foord, S.M.; Wise, A.; Dowell, S.J. The
843   Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain
844   carboxylic acids. *J. Biol. Chem.*, **2003**, *278*, 11312-11319.

845   41. Kelly, C.J.; Zheng, L.; Campbell, E.L.; Saeedi, B.; Scholz, C.C.; Bayless, A.J.; Wilson, K.E.; Glover, L.E.;
846   Kominsky, D.J.; Magnuson, A.; Weir, T.L.; Ehrentraut, S.F.; Pickel, C.; Kuhn, K.A.; Lanis, J.M.; Nguyen, V.;
847   Taylor, C.T.; Colgan, S.P. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial
848   HIF augments tissue barrier function. *Cell Host Microbe*, **2015**, *17*, 662-671.

849   42. Di Martino, M.L.; Campilongo, R.; Casalino, M.; Micheli, G.; Colonna, B.; Prosseda, G. Polyamines: emerging
850   players in bacteria-host interactions. *Int. J. Med. Microbiol.*, **2013**, *303*, 484-91.

851   43. Chen, J.; Rao, J.N.; Zou, T.; Liu, L.; Marasa, B.S.; Xiao, L.; Zeng, X.; Turner, D.J.; Wang, J.Y. Polyamines are
852   required for expression of Toll-like receptor 2 modulating intestinal epithelial barrier integrity. *Am. J. Physiol.*
853   *Gastrointest. Liver Physiol.*, **2007**, *293*, G568-G576.

854   44. Liu, L.; Rao, J.N.; Zou, T.; Xiao, L.; Wang, P.Y.; Turner, D.J.; Gorospe, M.; Wang, J.Y. Polyamines regulate c-
855   Myc translation through Chk2-dependent HuR phosphorylation. *Mol. Biol. Cell.,* **2009**, *20*, 4885-4898.

856   45. Perez-Cano, F.J.; González-Castro, A.; Castellote, C.; Franch, A.; Castell, M. Influence of breast milk
857   polyamines on suckling rat immune system maturation. *Dev. Comp. Immunol.*, **2010**, *34*, 210-218.

858   46. Ma, L.; Ni, Y.; Wang, Z.; Tu, W.; Ni, L.; Zhuge, F.; Zheng, A.; Hu, L.; Zhao, Y.; Zheng, L.; Fu, Z. Spermidine
859   improves gut barrier integrity and gut microbiota function in diet-induced obese mice. *Gut Microbes*, **2020**, *12*,
860   1-19.

861   47. Miller-Fleming, L.; Olin-Sandoval, V.; Campbell, K.; Ralser, M. Remaining mysteries of molecular biology: the
862   role of polyamines in the cell. *J. Mol. Biol.,* **2015**, *427*, 3389-3406.

863   48. Gerner, E.W.; Meyskens, F.L. Polyamines and cancer: old molecules, new understanding. *Nat. Rev. Cancer*,

864   **2004**, *4*, 781-792.

865   49. Johnson, C.H.; Dejea, C.M.; Edler, D.; Hoang, L.T.; Santidrian, A.F.; Felding, B.H.; Ivanisevic, J.; Cho, K.;

866   Wick, E.C.; Hechenbleikner, E.M.; Uritboonthai, W.; Goetz, L.; Casero, R.A.; Pardoll, D.M.; White, J.R.; Patti,

867   G.J.; Sears, C.L.; Siuzdak, G. Metabolism links bacterial biofilms and colon carcinogenesis. *Cell Metab*., **2015**,

868   *21*, 891-897.

869   50. Liu, R.; Lin, X.; Li, Z.; Li, Q.; Bi, K. Quantitative metabolomics for investigating the value of polyamines in the

870   early diagnosis and therapy of colorectal cancer. *Oncotarget*, **2018**, *9*, 4583-4592.

871   51. Hayes, C.S.; Shicora, A.C.; Keough, M.P.; Snook, A.E.; Burns, M.R.; Gilmour, S.K. Polyamine-blocking

872   therapy reverses immunosuppression in the tumor microenvironment. *Cancer Immunol. Res.*, **2014**, *2*, 274–285.

873   52. Casero, R.A.; Murray Stewart, T.; Pegg, A.E. Polyamine metabolism and cancer: treatments, challenges and

874   opportunities. *Nat. Rev. Cancer,* **2018**, *18*, 681-695.

875   53. Pietrocola, F.; Pol, J.; Vacchelli, E.; Rao, S.; Enot, D.P.; Baracco, E.E.; Levesque, S.; Castoldi, F.; Jacquelot,

876   N.; Yamazaki, T.; Senovilla, L.; Marino, G.; Aranda, F.; Durand, S.; Sica, V.; Chery, A.; Lachkar, S.; Sigl, V.;

877   Bloy, N.; Buque, A.; Falzoni, S.; Ryffel, B.; Apetoh, L.; Di Virgilio, F.; Madeo, F.; Maiuri, M.C.; Zitvogel, L.;

878   Levine, B.; Penninger, J.M.; Kroemer, G. Caloric restriction mimetics enhance anticancer immunosurveillance.

879   *Cancer Cell,* **2016**, *30*, 147-160.

880   54. Francino, M.P. Early development of the gut microbiota and immune health. *Pathogens*, **2014**, *4*, 769-90.

881   55. Nakanishi, Y.; Sato, T.; Ohteki, T. Commensal Gram-positive bacteria initiates colitis by inducing

882   monocyte/macrophage mobilization. *Mucosal Immunol.*, **2015**, *8*, 152-160.

883   56. Thomas, C.M.; Versalovic, J. Probiotics-host communication modulation of signaling pathways in the intestine.

884   *Gut Microbes*, **2010**, *1*, 1-16.

885   57. Belkaid, Y. Role of the microbiota in immunity and inflammation. *Cell*, **2014**, *157*, 121-141.

886   58. Owaga, E.; Hsieh, R.H.; Mugendi, B.; Masuku, S.; Shih, C.K.; Chang, J.S. Th17 cells as potential probiotic

887   therapeutic targets in inflammatory bowel diseases. *Int. J. Mol. Sci*, **2015**, *16*, 20841-20858.

888   59. Mazmanian, S.; Round, J.; Kasper, D. A microbial symbiosis factor prevents intestinal inflammatory disease.

889   *Nature*, **2008**, *453*, 620-625.

890   60. Round, J.L.; Lee, S.M.; Li, J.; Tran, G.; Jabri, B.; Chatila, T.A.; Mazmanian, S.K. The Toll-like receptor 2

891   pathway establishes colonization by a commensal of the human microbiota. *Science*, **2011**, *332*, 974-977.

892   61. Shanahan, F.; Ghosh, T.S.; O'Toole, P.W. What is the definition of a healthy gut microbiome? *Gastroenterology*,

893   **2021**, *160*, 483-494.

894   62. Duvallet, C.; Gibbons, S.M.; Gurry, T.; Irizarry, R.A.; Alm, E.J. Meta-analysis of gut microbiome studies
895   identifies disease-specific and shared responses. *Nat. Commun.*, **2017**, *8*, 1784.

896   63. Kho, Z.Y.; Lal, S.K. The human gut microbiome - a potential controller of wellness and disease. *Front.*
897   *Microbiol.*, **2018**, *9*, 1835.

898   64. Cani, P.D.; Van Hul, M. Gut microbiota and obesity: causally linked? *Expert Rev. Gastroenterol Hepatol.*, **2020**,
899   *14,* 401-403.

900   65. Lloyd-Price, J.; Arze, C.; Ananthakrishnan, A.N.; Schirmer, M.; Avila-Pacheco, J.; Poon, T.W.; Andrews, E.;
901   Ajami, N.J.; Bonham, K.S.; Brislawn, C.J.; Casero, D.; Courtney, H.; Gonzalez, A.; Graeber, T.G.; Hall, A.B.;
902   Lake, K.; Landers, C.J.; Mallick, H.; Plichta, D.R.; Prasad, M.; Rahnavard, G.; Sauk, J.; Shungin, D.; Vázquez-
903   Baeza, Y.; White, R.A.; IBDMDB Investigators; Braun, J.; Denson, L.A.; Jansson, J.K.; Knight, R.; Kugathasan,
904   S.; McGovern, D.P.B.; Petrosino, J.F.; Stappenbeck, T.S.; Winter, H.S.; Clish, C.B.; Franzosa, E.A.; Vlamakis,
905   H.; Xavier, R.J.; Huttenhower, C. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.
906   *Nature*, **2019**, *569*, 655-662.

907   66. Khan, I.; Ullah, N.; Zha, L.; Bai, Y.; Khan, A.; Zhao, T.; Che, T.; Zhang, C. Alteration of gut Mmicrobiota in
908   inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome.
909   *Pathogens*, **2019**, *8*, 126.

910   67. Wong, S.H.; Yu, J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. *Nat.*
911   *Rev. Gastroenterol. Hepatol.*, **2019**, *16*, 690-704.

912   68. Sheflin, A.M.; Whitney, A.K.; Weir, T.L. Cancer-promoting effects of microbial dysbiosis. *Curr. Oncol. Rep.*,
913   **2014**, *16*, 406.

914   69. Candela, M.; Turroni, S.; Biagi, E.; Carbonero, F.; Rampelli, S.; Fiorentini, C.; Brigidi, P. Inflammation and
915   colorectal cancer, when microbiota-host mutualism breaks. *World J. Gastroenterol.*, **2014**, *20*, 908-922.

916   70. Farrell, J.J.; Zhang, L.; Zhou, H.; Chia, D.; Elashoff, D.; Akin, D.; Paster, B.J.; Joshipura, K.; Wong, D.T.
917   Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. *Gut*, **2012**, *61*,
918   582-588.

919   71. Gong, H.L.; Shi, Y.; Zhou, L.; Wu, C.P.; Cao, P.Y.; Tao, L.; Xu, C.; Hou, D.S.; Wang, Y.Z. The composition of
920   microbiome in larynx and the throat biodiversity between laryngeal squamous cell carcinoma patients and
921   control population. *PLoS One*, **2013**, *8*, e66476.

922   72. Sharma, V.; Chauhan, V.S.; Nath, G.; Kumar, A.; Shukla, V.K. Role of bile bacteria in gallbladder carcinoma.
923   *Hepato-gastroenterology*, **2007**, *54*, 1622-1625.

924　　73. Bhatt, A.P.; Redinbo, M.R.; Bultman, S.J. The role of the microbiome in cancer development and therapy. *CA*
925　　　　*Cancer J. Clin.*, **2017**, *67*, 326-344.

926　　74. Goodman, B.; Gardner, H. The microbiome and cancer. *J. Pathol.*, **2018**, *244*, 667-676.

927　　75. Chaffer, C.L.; Weinberg, R.A. How does multistep tumorigenesis really proceed? *Cancer Discov.*, **2015**, *5*, 22-
928　　　　24.

929　　76. Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal carcinoma:
930　　　　A general overview and future perspectives in colorectal cancer. *Int. J. Mol. Sci.*, **2017**, *18*, 197.

931　　77. Zhang, L.; Shay, J.W. Multiple roles of APC and its therapeutic implications in colorectal cancer. *J. Natl. Cancer*
932　　　　*Inst.*, **2017**, *109*, djw332.

933　　78. McCoy, A.N.; Araújo-Pérez, F.; Azcárate-Peril, A.; Yeh, J.J.; Sandler, R.S.; Keku, T.O. *Fusobacterium* is
934　　　　associated with colorectal adenomas. *PLoS One*, **2013**, *8*, e53653.

935　　79. Castellarin, M.; Warren, R.L.; Freeman, J.D.; Dreolini, L.; Krzywinski, M.; Strauss, J.; Barnes, R.; Watson, P.;
936　　　　Allen-Vercoe, E.; Moore, R.A.; Holt, R.A. *Fusobacterium nucleatum* infection is prevalent in human colorectal
937　　　　carcinoma. *Genome research*, **2012**, *22*, 299-306.

938　　80. Zheng, J.; Meng, J.; Zhao, S.; Singh, R.; Song, W. *Campylobacter* induced interleukin-8 secretion in polarized
939　　　　human intestinal epithelial cells requires *Campylobacter*-secreted cytolethal distending toxin- and Toll-like
940　　　　receptor-mediated activation of NF-kB. *Infect. Immun.*, **2008**, *76*, 4498-4508.

941　　81. Bullman, S.; Pedamallu, C.S.; Sicinska, E.; Clancy, T.E.; Zhang, X.; Cai, D.; Neuberg, D.; Huang, K.; Guevara,
942　　　　F.; Nelson, T.; Chipashvili, O.; Hagan, T.; Walker, M.; Ramachandran, A.; Diosdado, B.; Serna, G.; Mulet, N.;
943　　　　Landolfi, S.; Ramon, Y.; Cajal, S.; Fasani, R.; Aguirre, A.J.; Ng, K.; Élez, E.; Ogino, S.; Tabernero, J.; Fuchs,
944　　　　C.S.; Hahn, W.C.; Nuciforo, P.; Meyerson, M. Analysis of *Fusobacterium* persistence and antibiotic response
945　　　　in colorectal cancer. *Science*, **2017**, *358*, 1443-1448.

946　　82. Louis, P.; Flint, H.J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the
947　　　　human large intestine. *FEMS Microbiol. Lett.*, **2009**, *294*, 1-8.

948　　83. Tjalsma, H.; Boleij, A.; Marchesi, J.R.; Dutilh, B.E. A bacterial driver-passenger model for colorectal cancer:
949　　　　beyond the usual suspects. *Nat. Rev. Microbiol.*, **2012**, *10*, 575-582.

950　　84. Huycke, M.M.; Abrams, V.; Moore, D.R. *Enterococcus faecalis* produces extracellular superoxide and hydrogen
951　　　　peroxide that damages colonic epithelial cell DNA. *Carcinogenesis*, **2002**, *23*, 529-536.

952　　85. de Almeida, C.V.; Taddei, A.; Amedei, A. The controversial role of *Enterococcus faecalis* in colorectal cancer.
953　　　　*Therap. Adv. Gastroenterol.*, **2018**, *1*, 1756284818783606.

954   86. Toprak, N.U.; Yagci, A.; Gulluoglu, B.M.; Akin, M.L.; Demirkalem, P.; Celenk, T.; Soyletir G. A possible role

955   of *Bacteroides fragilis* enterotoxin in the aetiology of colorectal cancer. *Clin. Microbiol. Infect.*, **2006**, *12*, 782-

956   786.

957   87. Haghi, F.; Goli, E.; Mirzaei, B.; Zeighami, H. The association between fecal enterotoxigenic *B. fragilis* with

958   colorectal cancer. *BMC Cancer*, **2019**, *19*, 879.

959   88. Lara-Tejero, M.; Galán, J.E. Cytolethal distending toxin: limited damage as a strategy to modulate cellular

960   functions. *Trends Microbiol.,* **2002**, *10*, 147-152.

961   89. Ge, Z.; Rogers, A.B.; Feng, Y.; Lee, A.; Xu, S.; Taylor, N.S.; Fox, J.G. Bacterial cytolethal distending toxin

962   promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. *Cell.*

963   *Microbiol.,* **2007**, *9*, 2070-2080.

964   90. Guerra, L.; Guidi, R.; Slot, I.; Callegari, S.; Sompallae, R.; Pickett, C.L.; Åström, S.; Eisele, F.; Wolf, D.;

965   Sjögren, C.; Masucci, M.G.; Frisan, T. Bacterial genotoxin triggers FEN1-dependent RhoA activation,

966   cytoskeleton remodeling and cell survival. *J. Cell. Sci.*, **2011**, *124*, 2735-2742.

967   91. Martin, O.C.B.; Bergonzini, A.; D'Amico, F.; Chen, P.; Shay, J.W.; Dupuy, J.; Svensson, M.; Masucci, M.G.;

968   Frisan T. Infection with genotoxin-producing *Salmonella enterica* synergises with loss of the tumour suppressor

969   APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells. *Cell. Microbiol.*, **2019**,

970   *21*, e13099.

971   92. Wentling, G.K.; Metzger, P.P.; Dozois, E.J.; Chua, H.K.; Krishna, M. Unusual bacterial infections and colorectal

972   carcinoma - *Streptococcus bovis* and *Clostridium septicum*: report of three cases. *Dis. Colon Rectum*, **2006**, *49*,

973   1223-1227.

974   93. Kostic, A.D.; Chun, E.; Robertson, L. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and

975   modulates the tumor-immune microenvironment. *Cell Host Microbe*, **2013**, *14*, 207-215.

976   94. Boleij, A.; Tjalsma, H. The itinerary of *Streptococcus gallolyticus* infection in patients with colonic malignant

977   disease. *Lancet Infect. Dis.*, **2013**, *13*, 719-724.

978   95. Marchesi, J.R.; Dutilh, B.E.; Hall, N.; Peters, W.H.; Roelofs, R.; Boleij, A.; Tjalsma, H. Towards the human

979   colorectal cancer microbiome. *PLoS One*, **2011**, *6*, e20447.

980   96. Candela, M.; Guidotti, M.; Fabbri, A.; Brigidi, P.; Franceschi, C.; Fiorentini, C. Human intestinal microbiota:

981   cross-talk with the host and its potential role in colorectal cancer. *Crit. Rev. Microbiol*., **2011**, *37*, 1-14.

982   97. Dapito, D.H.; Mencin, A.; Gwak, G.Y.; Pradere, J.P.; Jang, M.K.; Mederacke, I.; Caviglia, J.M.; Khiabanian,

983   H.; Adeyemi, A.; Bataller, R.; Lefkowitch, J.H.; Bower, M.; Friedman, R.; Sartor, R.B.; Rabadan, R.; Schwabe,

984   R.F. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. *Cancer Cell.*, **2012**, 21, 504-

985   516.

986 98. Tremaroli, V.; Bäckhed, F. Functional interactions between the gut microbiota and host metabolism. *Nature*,

987   **2012**, *489*, 242-249.

988 99. Yoshimoto, S.; Loo, T.M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita,

989   H.; Hattori, M.; Honda, K.; Ishikawa, Y.; Hara, E.; Ohtani, N. Obesity-induced gut microbial metabolite

990   promotes liver cancer through senescence secretome. *Nature*, **2013**, *499*, 97-101.

991 100.Quante, M.; Bhagat, G.; Abrams, J.A.; Marache, F.; Good, P.; Lee, M.D.; Lee, Y.; Friedman, R.; Asfaha, S.;

992   Dubeykovskaya, Z.; Mahmood, U.; Figueiredo, J.L.; Kitajewski, J.; Shawber, C.; Lightdale, C.J.; Rustgi, A.K.;

993   Wang, T.C. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like

994   metaplasia. *Cancer Cell.*, **2012**, *21*, 36-51.

995 101. Ridlon, J.M.; Kang, D.; Hylemon, P.B. Bile salt biotransformations by human intestinal Bacteria. *J. Lipid Res.*,

996   **2006**, *47*, 241-259.

997 102. Eslami-S, Z.; Majidzadeh-A, K.; Halvaei, S.; Babapirali, F.; Esmaeili, R. Microbiome and breast cancer: New

998   role for an ancient population. *Front. Oncol.*, **2020**, *10*, 120.

999 103. Goedert, J.J.; Jones, G.; Hua, X.; Xu, X.; Yu, G.; Flores, R.; Falk, R.T.; Gail, M.H.; Shi, J.; Ravel, J.; Feigelson,

1000   H.S. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women:

1001   a population-based case-control pilot study. *J. Natl. Cancer Inst.*, **2015**, *107*, djv147.

1002 104. Plottel, C.S.; Blaser, M.J. Microbiome and malignancy. *Cell Host Microbe*, **2011**, *10*, 324-335.

1003 105. Gloux, K., Berteau, O.; El Oumami, H.; Beguet, F.; Leclerc, M.; Dore, J. A metagenomic beta-glucuronidase

1004   uncovers a core adaptive function of the human intestinal microbiome. *Proc. Natl. Acad. Sci. U.S.A.*, **2011**, *108*,

1005   4539-4546.

1006 106. Dabek, M.; McCrae, S.I.; Stevens, V.J.; Duncan, S.H.; Louis, P. Distribution of beta-glucosidase and beta-

1007   glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. *FEMS Microbiol. Ecol.*,

1008   **2008**, *66*, 487-495.

1009 107. McIntosh, F.M.; Maison, N.; Holtrop, G.; Young, P.; Stevens, V.J.; Ince, J.; Johnstone, A.M.; Lobley, G.E.;

1010   Flint, H.J.; Louis, P. Phylogenetic distribution of genes encoding beta-glucuronidase activity in human colonic

1011   bacteria and the impact of diet on faecal glycosidase activities. *Environ. Microbiol.*, **2012**, *14*, 1876-1887.

1012 108. Rizkallah, M.R.; Saad, R.; Aziz, R.K. The Human Microbiome Project, personalized medicine and the birth of

1013   pharmacomicrobiomics. *Curr. Pharmacogenomics Pers. Med.*, **2010**, 8, 182-193.

1014   109. Alexander, J.L.; Wilson, I.D.; Teare, J.; Marchesi, J.R.; Nicholson, J.K.; Kinross, J.M. Gut microbiota
1015   modulation of chemotherapy efficacy and toxicity. *Nat. Rev. Gastroenterol. Hepatol.*, **2017**, *14*, 356-365.

1016   110. Roy, S.; Trinchieri, G. Microbiota: A key orchestrator of cancer therapy. *Nat. Rev. Cancer*, **2017**, *17*, 271-285.

1017   111. Nayak, R.R.; Turnbaugh, P.J. Mirror, mirror on the wall: Which microbiomes will help heal them all? *BMC*
1018   *Med.*, **2016**, *14*, 72.

1019   112. Fessler, J.L.; Gajewski, T.F. The microbiota: A new variable impacting cancer treatment outcomes. *Clin. Cancer*
1020   *Res.*, **2017**, *23*, 3229-3231.

1021   113. Nauts, H.C.; Swift, W.E.; Coley, B.L. The treatment of malignant tumors by bacterial toxins as developed by
1022   the late William B. Coley, M.D., reviewed in the light of modern research. *Cancer Res.*, **1946**, 205-216.

1023   114. McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. *IOWA*
1024   *Orthop. J.*, **2006**, *26*, 154-158.

1025   115. Zbar, B.; Bernstein, I.; Tanaka, T.; Rapp, H.J. Tumor immunity produced by the intradermal inoculation of
1026   living tumor cells and living *Mycobacterium bovis* (strain BCG). *Science*, **1970**, *170*, 1217-1218.

1027   116. Aso, Y.; Akazan, H. Prophylactic effect of a *Lactobacillus casei* preparation on the recurrence of superficial
1028   bladder cancer. *BLP Study Group Urol. Int.*, **1992**, *49*, 125-129.

1029   117. Hoesl, C.E.; Altwein, J.E. The probiotic approach: An alternative treatment option in urology. *Eur. Urol.*, **2005**,
1030   *47*, 288-296.

1031   118. Vivarelli, S.; Salemi, R.; Candido, S.; Falzone, L.; Santagati, M.; Stefani, S.; Torino, F.; Banna, G.L.; Tonini,
1032   G.; Libra, M. Gut microbiota and cancer: From pathogenesis to therapy. *Cancers*, **2019**, *11*, 38.

1033   119. Stebbing, J.; Dalgleish, A.; Gifford-Moore, A.; Martin, A.; Gleeson, C.; Wilson, G.; Brunet, L.R.; Grange, J.;
1034   Mudan, S. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal
1035   IMM-101 in melanoma. *Ann. Oncol.*, **2012**, *23*, 1314-1319.

1036   120. Dalgleish, A.G.; Stebbing, J.; Adamson, D.J.; Arif, S.S.; Bidoli, P.; Chang, D.; Cheeseman, S.; Diaz-Beveridge,
1037   R.; Fernandez-Martos, C.; Glynne-Jones, R.; Granetto, C.; Massuti, B.; McAdam, K.; McDermott, R.; Martín,
1038   A.J.; Papamichael, D.; Pazo-Cid, R.; Vieitez, J.M.; Zaniboni, A.; Carroll, K.J.; Wagle, S.; Gaya, A.; Mudan, S.S.
1039   Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic
1040   cancer. *Br. J. Cancer.*, **2016**, *115*, 789-796.

1041   121. Toso, J.F.; Gill, V.J.; Hwu, P.; Marincola, F.M.; Restifo, N.P.; Schwartzentruber, D.J.; Sherry, R.M.; Topalian,
1042   S.L.; Yang, J.C.; Stock, F.; Freezer, L.J.; Morton, K.E.; Seipp, C.; Haworth, L.; Mavroukakis, S.; White, D.;
1043   MacDonald, S.; Mao, J.; Sznol, M.; Rosenberg, S.A. Phase I study of the intravenous administration of attenuated
1044   Salmonella typhimurium to patients with metastatic melanoma. *J. Clin. Oncol.*, **2002**, *20*, 142-152.

1045 122. Nemunaitis, J.; Cunningham, C.; Senzer, N.; Kuhn, J.; Cramm, J.; Litz, C.; Cavagnolo, R.; Cahill, A.; Clairmont,
1046 C.; Sznol, M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase
1047 gene in refractory cancer patients. *Cancer Gene Ther.*, **2003**, *10*, 737-744.

1048 123. Kramer, M.G.; Masner, M.; Ferreira, F.A.; Hoffman, R.M. Bacterial therapy of cancer: Promises, limitations,
1049 and insights for future directions. *Front. Microbiol.*, **2018**, *9*, 16.

1050 124. Schwabe, R.F.; Jobin, C. The microbiome and cancer. *Nat. Rev. Cancer*, **2013**, *13*, 800-812.

1051 125. DeVita, V.T.; Chu, E. A history of cancer chemotherapy. *Cancer Res.*, **2008**, *68*, 8643-8653.

1052 126. McGranahan, N.; Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer
1053 evolution. *Cancer Cell.*, **2015**, *27*, 15-26.

1054 127. Allison, J.P.; McIntyre, B.W.; Bloch, D. Tumor-specific antigen of murine T-lymphoma defined with
1055 monoclonal antibody. *J. Immunol.*, **1982**, *129*, 2293–300.

1056 128. Toh, H.C. Cancer immunotherapy-the end of the beginning. *Chin. Clin. Oncol.*, **2018**, *7*, 12.

1057 129. Dzutsev, A.; Goldszmid, R.S.; Viaud, S.; Zitvogel, L.; Trinchieri, G. The role of the microbiota in inflammation,
1058 carcinogenesis, and cancer therapy. *Eur. J. Immunol.*, **2015**, *45*, 17-31.

1059 130. Mathijssen, R.H.; van Alphen, R.J.; Verweij, J.; Loos, W.J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical
1060 pharmacokinetics and metabolism of irinotecan (CPT-11). *Clin. Cancer Res.*, **2001**, *7*, 2182-94.

1061 131.Takasuna, K.; Hagiwara, T.; Hirohashi, M.; Kato, M.; Nomura, M.; Nagai, E.; Yokoi, T.; Kamataki, T.
1062 Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor
1063 camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. *Cancer Res.*, **1996**, *56*, 3752-7.

1064 132.Cheng, K.W.; Tseng, C.H.; Tzeng, C.C.; Leu, Y.L.; Cheng, T.C.; Wang, J.Y.; Chang, J.M.; Lu, Y.C.; Cheng,
1065 C.M.; Chen, I.J.; Cheng, Y.A.; Chen, Y.L.; Cheng, T.L. Pharmacological inhibition of bacterial β-glucuronidase
1066 prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. *Pharmacol. Res.,* **2019**,
1067 *139*, 41-49.

1068 133. Iida, N.; Dzutsev, A.; Stewart, C.A.; Smith, L.; Bouladoux, N.; Weingarten, R.A.; Molina, D.A.; Salcedo, R.;
1069 Back, T.; Cramer, S.; Dai, R.M.; Kiu, H.; Cardone, M., Naik, S.; Patri, A.K.; Wang, E.; Marincola, F.M. Frank,
1070 K.M.; Belkaid, Y.; Trinchieri, G.; Goldszmid, R.S. Commensal bacteria control cancer response to therapy by
1071 modulating the tumor microenvironment. *Science*, **2013**, *342*, 967-970.

1072 134. Gui, Q.F.; Lu, H.F.; Zhang, C.X.; Xu, Z.R.; Yang, Y.H. Well-balanced commensal microbiota contributes to
1073 anti-cancer response in a lung cancer mouse model. *Genet. Mol. Res.*, **2015**, *14*, 5642-5651.

1074 135. Viaud, S.; Saccheri, F.; Mignot, G.; Yamazaki, T.; Daillère, R.; Hannani, D.; Enot, D.P.; Pfirschke, C.; Engblom,
1075 C.; Pittet, M.J.; Schlitzer, A.; Ginhoux, F.; Apetoh, L.; Chachaty, E.; Woerther, P.L.; Eberl, G.; Bérard, M.;

1076 Ecobichon, C.; Clermont, D.; Bizet, C.; Gaboriau-Routhia, V.; Cerf-Bensussan, N.; Opolon, P.; Yessaad, N.;

1077 Vivier, E.; Ryffel, B.; Elson, C.O.; Doré, J.; Kroemer, G.; Lepage, P.; Boneca, I.G.; Ghiringhelli, F.; Zitvogel,

1078 L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science,* **2013**, *342*,

1079 971-976.

1080 136. Zitvogel, L.; Pitt, J.M.; Daillère, R.; Smyth, M.J.; Kroemer, G. Mouse models in oncoimmunology. *Nat. Rev.*

1081 *Cancer.*, **2016**, *16*, 759-773.

1082 137. Ivanov, I.I.; Frutos, R.; Manel, N.; Yoshinaga, K.; Rifkin, D.B.; Sartor, R.B.; Finlay, B.B.; Littman, D.R.

1083 Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small

1084 intestine. *Cell Host Microbe*, **2008**, 4, 337-349.

1085 138. Daillère, R.; Vétizou, M.; Waldschmitt, N.; Yamazaki, T.; Isnard, C.; Poirier-Colame, V.; Duong, C.P.M.;

1086 Flament, C.; Lepage, P.; Roberti, M.P.; Routy, B.; Jacquelot, N.; Apetoh, L.; Becharef, S.; Rusakiewicz, S.;

1087 Langella, P.; Sokol, H.; Kroemer, G.; Enot, D.; Roux, A.; Eggermont, A.; Tartour, E.; Johannes, L.; Woerther,

1088 P.L.; Chachaty, E.; Soria, J.C.; Golden, E.; Formenti, S.; Plebanski, M.; Madondo, M.; Rosenstiel, P.; Raoult,

1089 D.; Cattoir, V.; Boneca, I.G.; Chamaillard, M.; Zitvogel, L. *Enterococcus hirae* and *Barnesiella intestinihominis*

1090 facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. *Immunity*, **2016**, *45*, 931-943.

1091 139. Jahrsdörfer, B.; Weiner, G.J. CpG oligodeoxynucleotides as immunotherapy in cancer. *Update Cancer Ther.,*

1092 **2008**, *3*, 27-32.

1093 140. Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillère, R.; Fluckiger, A.; Messaoudene,

1094 M.; Rauber, C.; Roberti, M.P.; Fidelle, M.; Flament, C.; Poirier-Colame, V., Opolon, P.; Klein, C.; Iribarren, K.;

1095 Mondragón, L.; Jacquelot, N.; Qu, B.; Ferrere, G.; Clémenson, C.; Mezquita, L.; Masip, J.R.; Naltet, C.;

1096 Brosseau, S.; Kaderbhai, C.; Richard, C.; Rizvi, H.; Levenez, F.; Galleron, N.; Quinquis, B., Pons, N.; Ryffel,

1097 B.; Minard-Colin, V.; Gonin, P.; Soria, J.C.; Deutsch, E.; Loriot, Y.; Ghiringhelli, F.; Zalcman, G.; Goldwasser,

1098 F.; Escudier, B.; Hellmann, M.D.; Eggermont, A.; Raoult, D.; Albiges, L.; Kroemer, G.; Zitvogel, L. Gut

1099 microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*, **2018**, *359*,

1100 91-97.

1101 141. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.;

1102 Vicente, D.; Hoffman, K.; Wei, S.C.; Cogdill, A.P.; Zhao, L.; Hudgens, C.W.; Hutchinson, D.S.; Manzo, T.;

1103 Petaccia de Macedo, M.; Cotechini, T.; Kumar, T.; Chen, W.S.; Reddy, S.M.; Szczepaniak Sloane, R.; Galloway-

1104 Pena, J.; Jiang, H.; Chen, P.L.; Shpall, E.J.; Rezvani, K.; Alousi, A.M.; Chemaly, R.F.; Shelburne, S.; Vence,

1105 L.M.; Okhuysen, P.C.; Jensen, V.B.; Swennes, A.G.; McAllister, F.; Marcelo Riquelme Sanchez, E.; Zhang, Y.,

1106 Le Chatelier, E.; Zitvogel, L.; Pons, N.; Austin-Breneman, J.L.; Haydu, L.E.; Burton, E.M.; Gardner, J.M.;

1107   Sirmans, E.; Hu, J.; Lazar, A.J.; Tsujikawa, T.; Diab, A.; Tawbi, H.; Glitza, I.C.; Hwu, W.J.; Patel, S.P.;

1108   Woodman, S.E.; Amaria, R.N.; Davies, M.A.; Gershenwald, J.E.; Hwu, P.; Lee, J.E.; Zhang, J.; Coussens, L.M.;

1109   Cooper, Z.A.; Futreal, P.A.; Daniel, C.R.; Ajami, N.J.; Petrosino, J.F.; Tetzlaff, M.T.; Sharma, P.; Allison, J.P.;

1110   Jenq, R.R.; Wargo, J.A. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

1111   *Science*, **2018**, *359*, 97-103

1112   142. Matson, V.; Fessler, J.; Bao, R.; Chongsuwat, T.; Zha, Y.; Alegre, M.L.; Luke, J.J.; Gajewski, T.F. The

1113   commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*, **2018**,

1114   *359*, 104-108.

1115   143. Chen, Q.; Wang, C.; Chen, G.; Hu, Q.; Gu, Z. Delivery strategies for immune checkpoint blockade. *Adv.*

1116   *Healthc. Mater.*, **2018**, *7*, e1800424.

1117   144.Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their

1118   inhibition. *Am. J. Clin. Oncol.*, **2016**, *39*, 98-106.

1119   145. Vétizou, M.; Pitt, J.M.; Daillère, R.; Lepage, P.; Waldschmitt, N.; Flament, C.; Rusakiewicz, S.; Routy, B.;

1120   Roberti, M.P.; Duong, C.P.; Poirier-Colame, V.; Roux, A.; Becharef, S.; Formenti, S.; Golden, E.; Cording, S.;

1121   Eberl, G.; Schlitzer, A.; Ginhoux, F.; Mani, S.; Yamazaki, T.; Jacquelot, N.; Enot, D.P.; Bérard, M.; Nigou, J.;

1122   Opolon, P.; Eggermont, A.; Woerther, P.L.; Chachaty, E.; Chaput, N.; Robert, C.; Mateus, C.; Kroemer, G.;

1123   Raoult, D.; Boneca, I.G.; Carbonnel, F.; Chamaillard, M.; Zitvogel, L. Anticancer immunotherapy by CTLA-4

1124   blockade relies on the gut microbiota. *Science*, **2015**, *350*, 1079-1084.

1125   146. Sivan, A.; Corrales, L.; Hubert, N.; Williams, J.B.; Aquino-Michaels, K.; Earley, Z.M.; Benyamin, F.W.; Lei,

1126   Y.M.; Jabri, B.; Alegre, M.L.; Chang, E.B.; Gajewski, T.F. Commensal *Bifidobacterium* promotes antitumor

1127   immunity and facilitates anti-PD-L1 efficacy. *Science*, **2015**, *350*, 1084-1089.

1128   147. Gharaibeh, R.Z.; Jobin, C. Microbiota and cancer immunotherapy: in search of microbial signals. *Gut*, **2019**,

1129   *68*, 385-388.

1130   148. Limeta, A.; Ji, B.; Levin, M.; Gatto, F.; Nielsen, J. Meta-analysis of the gut microbiota in predicting response

1131   to cancer immunotherapy in metastatic melanoma. *JCI Insight*, **2020**, *5*, e140940.

1132   149. Tanoue, T.; Morita, S.; Plichta, D.R.; Skelly, A.N.; Suda, W.; Sugiura, Y.; Narushima, S.; Vlamakis, H.; Motoo,

1133   I.; Sugita, K.; Shiota, A.; Takeshita, K.; Yasuma-Mitobe, K.; Riethmacher, D.; Kaisho, T.; Norman, J.M.;

1134   Mucida, D.; Suematsu, M.; Yaguchi, T.; Bucci, V.; Inoue, T.; Kawakami, Y.; Olle, B.; Roberts, B.; Hattori, M.;

1135   Xavier, R.J.; Atarashi, K.; Honda, K. A defined commensal consortium elicits CD8 T cells and anti-cancer

1136   immunity. *Nature*, **2019**, *565*, 600-605.

1137 150. Mager, L.F.; Burkhard, R.; Pett, N.; Cooke, N.C.A.; Brown, K.; Ramay, H.; Paik, S.; Stagg, J.; Groves, R.A.;
1138   Gallo, M.; Lewis, I.A.; Geuking, M.B.; McCoy, K.D. Microbiome-derived inosine modulates response to
1139   checkpoint inhibitor immunotherapy. *Science*, **2020**, *369*, 1481-1489.

1140 151. Li, Y.; Elmén, L.; Segota, I.; Xian, Y.; Tinoco, R.; Feng, Y.; Fujita, Y.; Segura Muñoz, R.R.; Schmaltz, R.;
1141   Bradley, L.M.; Ramer-Tait, A.; Zarecki, R.; Long, T.; Peterson, S.N.; Ronai, Z.A. Prebiotic-induced anti-tumor
1142   immunity attenuates tumor growth. *Cell Rep.*, **2020**, *30*, 1753-1766.e6.

1143 152. Jenq, R.R.; van den Brink, M.R. Allogeneic haematopoietic stem cell transplantation: individualized stem cell
1144   and immune therapy of cancer. *Nat. Rev. Cancer*, **2010**, *10*, 213-221.

1145 153. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. *N. Engl. J.*
1146   *Med.,* **2017**, *377*, 2167-2179.

1147 154.Peled, J.U.; Gomes, A.L.C.; Devlin, S.M.; Littmann, E.R.; Taur, Y.; Sung, A.D.; Weber, D.; Hashimoto, D.;
1148   Slingerland, A.E.; Slingerland, J.B.; Maloy, M.; Clurman, A.G.; Stein-Thoeringer, C.K.; Markey, K.A.;
1149   Docampo, M.D.; Burgos da Silva, M.; Khan, N.; Gessner, A.; Messina, J.A.; Romero, K.; Lew, M.V.; Bush, A.;
1150   Bohannon, L.; Brereton, D.G.; Fontana, E.; Amoretti, L.A.; Wright, R.J.; Armijo, G.K.; Shono, Y.; Sanchez-
1151   Escamilla, M.; Castillo Flores, N.; Alarcon Tomas, A.; Lin, R.J.; Yáñez San Segundo, L.; Shah, G.L.; Cho, C.;
1152   Scordo, M.; Politikos, I.; Hayasaka, K.; Hasegawa, Y.; Gyurkocza, B.; Ponce, D.M.; Barker, J.N.; Perales, M.A.;
1153   Giralt, S.A.; Jenq, R.R.; Teshima, T.; Chao, N.J.; Holler, E.; Xavier, J.B.; Pamer, E.G.; van den Brink, M.R.M.
1154   Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. *N. Engl. J. Med.*, **2020**,
1155   *382*, 822-834.

1156 155. Ingham, A.C.; Kielsen, K.; Cilieborg, M.S.; Lund, O.; Holmes, S.; Aarestrup, F.M.; Müller, K.G.; Pamp, S.J.
1157   Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic
1158   hematopoietic stem cell transplantation. *Microbiome*, **2019**, *7*, 131.

1159 156. Zama, D.; Bossù, G.; Leardini, D.; Muratore, E.; Biagi, E.; Prete, A.; Pession, A.; Masetti, R. Insights into the
1160   role of intestinal microbiota in hematopoietic stem-cell transplantation. *Ther. Adv. Hematol.*, **2020**, *11*,
1161   2040620719896961.

1162 157. Taur, Y.; Xavier, J.B.; Lipuma, L.; Ubeda, C.; Goldberg, J.; Gobourne, A.; Lee, Y.J.; Dubin, K.A.; Socci, N.D.;
1163   Viale, A.; Perales, M.A.; Jenq, R.R.; van den Brink. M.R.; Pamer, E.G. Intestinal domination and the risk of
1164   bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. *Clin. Infect. Dis.*, **2012**,
1165   *55*, 905-914.

1166 158. Taur, Y.; Jenq, R.R.; Perales, M.A.; Littmann, E.R.; Morjaria, S.; Ling, L.; No, D.; Gobourne, A.; Viale, A.;
1167   Dahi, P.B.; Ponce, D.M.; Barker, J.N.; Giralt, S.; van den Brink, M.; Pamer, E.G. The effects of intestinal tract

bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. *Blood*, **2014**, *124*, 1174-1182.

159. Jenq, R.R.; Ubeda, C.; Taur, Y.; Menezes, C.C.; Khanin, R.; Dudakov, J.A.; Liu, C.; West, M.L.; Singer, N.V.; Equinda, M.J.; Gobourne, A.; Lipuma, L.; Young, L.F.; Smith, O.M.; Ghosh, A.; Hanash, A.M.; Goldberg, J. D.; Aoyama, K.; Blazar, B.R.; Pamer, E.G., van den Brink, M.R. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. *J. Exp. Med.*, **2012**, *209*, 903-11.

160. Shono, Y.; Docampo, M.D.; Peled, J.U.; Perobelli, S.M.; Velardi, E.; Tsai, J.J.; Slingerland, A.E.; Smith, O.M.; Young, L.F.; Gupta, J.; Lieberman, S.R.; Jay, H.V.; Ahr, K.F.; Porosnicu Rodriguez, K.A.; Xu, K.; Calarfiore, M.; Poeck, H.; Caballero, S.; Devlin, S.M.; Rapaport, F.; Dudakov, J.A.; Hanash, A.M.; Gyurkocza, B.; Murphy, G.F.; Gomes, C.; Liu, C.; Moss, E.L.; Falconer, S.B.; Bhatt, A.S.; Taur, Y.; Pamer, E.G.; van den Brink, M.R.M.; Jenq, R.R. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. *Sci. Transl. Med.*, **2016**, *8*, 339ra71.

161. Heimesaat, M.M.; Nogai, A.; Bereswill, S.; Plickert, R.; Fischer, A.; Loddenkemper, C.; Steinhoff, U.; Tchaptchet, S.; Thiel, E.; Freudenberg, M.A.; Göbel, U.B.; Uharek, L. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. *Gut*, **2010**, *59*, 1079-1087.

162. Eriguchi, Y.; Takashima, S.; Oka, H.; Shimoji, S.; Nakamura, K.; Uryu, H.; Shimoda, S.; Iwasaki, H.; Shimono, N.; Ayabe, T.; Akashi, K.; Teshima, T. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. *Blood*, **2012**, *120*, 223-231.

163. Biagi, E.; Zama, D.; Nastasi, C.; Consolandi, C.; Fiori, J.; Rampelli, S.; Turroni, S.; Centanni, M.; Severgnini, M.; Peano, C.; de Bellis, G.; Basaglia, G.; Gotti, R.; Masetti, R.; Pession, A.; Brigidi, P.; Candela, M. Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT. *Bone Marrow Transplant.*, **2015**, *50*, 992-998.

164. Biagi, E.; Zama, D.; Rampelli, S.; Turroni, S.; Brigidi, P.; Consolandi, C.; Severgnini, M.; Picotti, E.; Gasperini, P.; Merli, P.; Decembrino, N.; Zecca, M.; Cesaro, S.; Faraci, M.; Prete, A.; Locatelli, F.; Pession, A.; Candela, M.; Masetti, R. Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders. *BMC Med. Genomics*, **2019**, *12*, 49.

165. Han, L.; Zhang, H.; Chen, S.; Zhou, L.; Li, Y.; Zhao, K.; Huang, F.; Fan, Z.; Xuan, L.; Zhang, X.; Dai, M.; Lin, Q.; Jiang, Z.; Peng, J.; Jin, H.; Liu, Q. Intestinal microbiota can predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. *Biol. Blood Marrow Transpl.*, **2019**, *25*, 1944-1955.

1198 166. Mathewson, N.D.; Jenq, R.; Mathew, A.V.; Koenigsknecht, M.; Hanash, A.; Toubai, T.; Oravecz-Wilson, K.;
1199 Wu, S.R.; Sun, Y.; Rossi, C.; Fujiwara, H.; Byun, J.; Shono, Y.; Lindemans, C.; Calafiore, M.; Schmidt, T.M.;
1200 Honda, K.; Young, V.B.; Pennathur, S.; van den Brink, M.; Reddy, P. Gut microbiome-derived metabolites
1201 modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. *Nat. Immunol.*, **2016**, *17*, 505-
1202 513.

1203 167. Atarashi, K.; Tanoue, T.; Oshima, K.; Suda, W.; Nagano, Y.; Nishikawa, H.; Fukuda, S.; Saito, T.; Narushima,
1204 S.; Hase, K.; Kim, S.; Fritz, J.V.; Wilmes, P.; Ueha, S.; Matsushima, K.; Ohno, H.; Olle, B.; Sakaguchi, S.;
1205 Taniguchi, T.; Morita, H.; Hattori, M.; Honda, K. Treg induction by a rationally selected mixture of clostridia
1206 strains from the human microbiota. *Nature*, **2013**, *500*, 232-236.

1207 168. Liu, X.; Mao, B.; Gu, J.; Wu, J.; Cui, S.; Wang, G.; Zhao, J.; Zhang, H.; Chen, W. Blautia-a new functional
1208 genus with potential probiotic properties? *Gut Microbes*, **2021**, *13*, 1-21.

1209 169. Jenq, R.R.; Taur, Y.; Devlin, S.M.; Ponce, D.M.; Goldberg, J.D.; Ahr, K.F.; Littmann, E.R.; Ling, L.; Gobourne,
1210 A.C.; Miller, L.C.; Docampo, M.D.; Peled, J.U.; Arpaia, N.; Cross, J.R.; Peets, T.K.; Lumish, M.A.; Shono, Y.;
1211 Dudakov, J.A.; Poeck, H.; Hanash, A.M.; Barker, J.M.; Perales, M.A.; Giralt, S.A.; Pamer, E.G.; van den Brink,
1212 M.R. Intestinal *Blautia* is associated with reduced death from graft-versus-host disease. *Biol. Blood Marrow*
1213 *Transplant.*, **2015**, *21*, 1373-1383.

1214 170. D'Amico, F.; Biagi, E.; Rampelli, S.; Fiori, J.; Zama, D.; Soverini, M.; Barone, M.; Leardini, D.; Muratore, E.;
1215 Prete, A.; Gotti, R.; Pession, A.; Masetti, R.; Brigidi, P.; Turroni, S.; Candela, M. Enteral nutrition in pediatric
1216 patients undergoing hematopoietic SCT promotes the recovery of gut microbiome homeostasis. *Nutrients*, **2019**,
1217 *11*, 2958.

1218 171. Staffas, A.; Burgos da Silva, M.; Slingerland, A.E.; Lazrak, A.; Bare, C.J.; Holman, C.D.; Docampo, M.D.;
1219 Shono, Y.; Durham, B.; Pickard, A.J.; Cross, J.R.; Stein-Thoeringer, C.; Velardi, E.; Tsai, J.J.; Jahn, L.; Jay, H.;
1220 Lieberman, S.; Smith, O.M.; Pamer, E.G.; Peled, J.U.; Cohen, D.E.; Jenq, R.R.; van den Brink, M.R.M.
1221 Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone marrow
1222 transplantation in Mice. *Cell Host Microbe*, **2018**, *23*, 447-457.

1223 172. Geller, L.T.; Barzily-Rokni, M.; Danino, T.; Jonas, O.H.; Shental, N.; Nejman, D.; Gavert, N.; Zwang, Y.;
1224 Cooper, Z.A.; Shee, K.; Thaiss, C.A.; Reuben, A.; Livny, J.; Avraham, R.; Frederick, D.T.; Ligorio, M.;
1225 Chatman, K.; Johnston, S.E.; Mosher, C.M.; Brandis, A.; Fuks, G.; Gurbatri, C.; Gopalakrishnan, V.; Kim, M.;
1226 Hurd, M.W.; Katz, M.; Fleming, J.; Maitra, A.; Smith, D.A.; Skalak, M.; Bu, J.; Michaud, M.; Trauger, S.A.;
1227 Barshack, I.; Golan, T.; Sandbank, J.; Flaherty, K.T.; Mandinova, A.; Garrett, W.S.; Thayer, S.P.; Ferrone, C.R.;
1228 Huttenhower, C.; Bhatia, S.N.; Gevers, D.; Wargo, J.A.; Golub, T.R.; Straussman, R. Potential role of intratumor

1229   bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science*, **2017**, *357*, 1156-
1230   1160.

1231   173. Barrett, M.; Hand, C.K.; Shanahan, F.; Murphy, T.; O'Toole, P.W. Mutagenesis by microbe: the role of the
1232   microbiota in shaping the cancer genome. *Trends Cancer*, **2020**, *6*, 277-287.

1233   174. Pleguezuelos-Manzano, C.; Puschhof, J.; Rosendahl Huber, A.; van Hoeck, A.; Wood, H.M.; Nomburg, J.;
1234   Gurjao, C.; Manders, F.; Dalmasso, G.; Stege, P.B.; Paganelli, F.L.; Geurts, M.H.; Beumer, J.; Mizutani, T.;
1235   Miao, Y.; van der Linden, R.; van der Elst, S.; Genomics England Research Consortium, Garcia, K.C.; Top, J.;
1236   Willems, R.J.L.; Giannakis, M.; Bonnet, R.; Quirke, P.; Meyerson, M.; Cuppen, E.; van Boxtel, R.; Clevers, H.
1237   Mutational signature in colorectal cancer caused by genotoxic pks+ *E. coli*. *Nature*, **2020**, *580*, 269-273.

1238   175. Brennan, C.A.; Garrett, W.S. *Fusobacterium nucleatum* - symbiont, opportunist and oncobacterium. *Nat. Rev.*
1239   *Microbiol.*, **2019**, *17*, 156-166.

1240   176. Sepich-Poore, G.D.; Zitvogel, L.; Straussman, R.; Hasty, J.; Wargo, J.A.; Knight, R. The microbiome and
1241   human cancer. *Science*, **2021**, *71*, eabc4552.

1242   177. Nejman, D.; Livyatan, I.; Fuks, G.; Gavert, N.; Zwang, Y.; Geller, L.T.; Rotter-Maskowitz, A.; Weiser, R.;
1243   Mallel, G.; Gigi, E.; Meltser, A.; Douglas, G.M.; Kamer, I.; Gopalakrishnan, V.; Dadosh, T.; Levin-Zaidman,
1244   S.; Avnet, S.; Atlan, T.; Cooper, Z.A.; Arora, R.; Cogdill, A.P.; Khan, M.A.W.; Ologun, G.; Bussi, Y.;
1245   Weinberger, A.; Lotan-Pompan, M.; Golani, O.; Perry, G.; Rokah, M.; Bahar-Shany, K.; Rozeman, E.A.; Blank,
1246   C.U.; Ronai, A.; Shaoul, R.; Amit, A.; Dorfman, T.; Kremer, R.; Cohen, Z.R.; Harnof, S.; Siegal, T.; Yehuda-
1247   Shnaidman, E.; Gal-Yam, E.N.; Shapira, H.; Baldini, N.; Langille, M.G.I.; Ben-Nun, A.; Kaufman, B.; Nissan,
1248   A.; Golan, T.; Dadiani, M.; Levanon, K.; Bar, J.; Yust-Katz, S.; Barshack, I.; Peeper, D.S.; Raz, D.J.; Segal, E.;
1249   Wargo, J.A.; Sandbank, J.; Shental, N.; Straussman, R. The human tumor microbiome is composed of tumor
1250   type-specific intracellular bacteria. *Science*, **2020**, *368*, 973-980.

1251   178. Poore, G.D.; Kopylova, E.; Zhu, Q.; Carpenter, C.; Fraraccio, S.; Wandro, S.; Kosciolek, T.; Janssen, S.;
1252   Metcalf, J.; Song, S.J.; Kanbar, J.; Miller-Montgomery, S.; Heaton, R.; Mckay, R.; Patel, S.P.; Swafford, A.D.;
1253   Knight, R. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. *Nature*, **2020**, *579*,
1254   567-574.

1255   179. Errington, J. Cell wall-deficient, L-form bacteria in the 21st century: a personal perspective. *Biochem. Soc.*
1256   *Trans.*, **2017**, *45*, 287-295.

1257   180. Parhi, L.; Alon-Maimon, T.; Sol, A.; Nejman, D.; Shhadeh, A.; Fainsod-Levi, T.; Yajuk, O.; Isaacson, B.; Abed,
1258   J.; Maalouf, N.; Nissan, A.; Sandbank, J.; Yehuda-Shnaidman, E.; Ponath, F.; Vogel, J.; Mandelboim, O.;

1259 Granot, Z.; Straussman, R.; Bachrach, G. Breast cancer colonization by *Fusobacterium nucleatum* accelerates
1260 tumor growth and metastatic progression. *Nat. Commun.*, **2020**, *11*, 3259.

1261 181.Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N.; Chen, Y.;
1262 Chen, H.; Hong, J.; Zou, W.; Fang, J.Y. *Fusobacterium nucleatum* promotes chemoresistance to colorectal
1263 cancer by modulating autophagy. *Cell*, **2017**, *170*, 548-563.

1264 182. Riquelme, E.; Zhang, Y.; Zhang, L.; Montiel, M.; Zoltan, M.; Dong, W.; Quesada, P.; Sahin, I.; Chandra, V.;
1265 San Lucas, A.; Scheet, P.; Xu, H.; Hanash, S.M.; Feng, L.; Burks, J.K.; Do, K.A.; Peterson, C.B.; Nejman, D.;
1266 Tzeng, C.D.; Kim, M.P.; Sears, C.L.; Ajami, N.; Petrosino, J.; Wood, L.D.; Maitra, A.; Straussman, R.; Katz,
1267 M.; White, J.R.; Jenq, R.; Wargo, J.; McAllister, F. Tumor Microbiome Diversity and Composition Influence
1268 Pancreatic Cancer Outcomes. *Cell*, **2019**, *178*, 795-806.

1269 183. Falzone, L.; Salomone, S.; Libra, M. Evolution of cancer pharmacological treatments at the turn of the third
1270 millennium. *Front. Pharmacol.*, **2018**, *9*, 1300.

1271 184. Helmink, B.A.; Khan, M.A.W.; Hermann, A.; Gopalakrishnan, V.; Wargo, J.A. The microbiome, cancer, and
1272 cancer therapy. *Nat. Med.*, **2019**, *25*, 377-388.

1273 185. Parida, S.; Sharma, D. The microbiome and cancer: Creating friendly neighborhoods and removing the foes
1274 within. *Cancer Res.*, **2021**, *81*, 790-800.

1275 186. Kaźmierczak-Siedlecka, K.; Daca, A.; Fic, M.; van de Wetering, T.; Folwarski, M.; Makarewicz, W.
1276 Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota
1277 transplantation, prebiotics, probiotics, and synbiotics. *Gut Microbes*, **2020**, *11*, 1518-1530.

1278 187. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.;
1279 Swanson, K.S.; Cani, P.D.; Verbeke, K.; Reid, G. Expert consensus document: The International Scientific
1280 Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.
1281 *Nat. Rev. Gastroenterol. Hepatol.*, **2017**, *14*, 491-502.

1282 188. Vandeputte, D.; Falony, G.; Vieira-Silva, S.; Wang, J.; Sailer, M.; Theis, S.; Verbeke, K.; Raes, J. Prebiotic
1283 inulin-type fructans induce specific changes in the human gut microbiota. *Gut*, **2017**, *66*, 1968-1974.

1284 189. Cunningham, M.; Azcarate-Peril, M.A.; Barnard, A.; Benoit, V.; Grimaldi, R.; Guyonnet, D.; Holscher, H.D.;
1285 Hunter, K.; Manurung, S.; Obis, D.; Petrova, M.I.; Steinert, R.E.; Swanson, K.S.; van Sinderen, D.; Vulevic, J.;
1286 Gibson, G.R. Shaping the future of probiotics and prebiotics. *Trends Microbiol.*, **2021**, S0966-842X(21)00005-
1287 6. [online ahead of print]. doi: 10.1016/j.tim.2021.01.003.

1288 190. Deehan, E.C.; Yang, C.; Perez-Muñoz, M.E.; Nguyen, N.K.; Cheng, C.C.; Triador, L.; Zhang, Z.; Bakal, J.A.;
1289   Walter, J. Precision microbiome modulation with discrete dietary fiber structures directs short-chain fatty acid
1290   production. *Cell Host Microbe*, **2020**, *27*, 389-404.

1291 191.Sasidharan, B.K.; Ramadass, B.; Viswanathan, P.N.; Samuel, P.; Gowri, M.; Pugazhendhi, S.; Ramakrishna,
1292   B.S. A phase 2 randomized controlled trial of oral resistant starch supplements in the prevention of acute
1293   radiation proctitis in patients treated for cervical cancer. *J. Cancer Res. Ther.*, **2019**, *15*, 1383-1391.

1294 192. Xie, X.; He, Y.; Li, H.; Yu, D.; Na, L.; Sun, T.; Zhang, D.; Shi, X.; Xia, Y.; Jiang, T.; Rong, S.; Yang, S.; Ma,
1295   X.; Xu, G. Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative
1296   colorectal cancer patients. *Nutrition*, **2019**, *61*, 132-142.

1297 193. García-Peris, P.; Velasco, C.; Lozano, M.A.; Moreno, Y.; Paron, L.; de la Cuerda, C.; Bretón, I.; Camblor, M.;
1298   García-Hernández, J.; Guarner, F.; Hernández, M. Effect of a mixture of inulin and fructo-oligosaccharide on
1299   *Lactobacillus* and *Bifidobacterium* intestinal microbiota of patients receiving radiotherapy: a randomised,
1300   double-blind, placebo-controlled trial. *Nutr. Hosp.*, **2012**, *27*, 1908-1915.

1301 194. Criscuolo, A.A.; Sesti, F.; Piccione, E.; Mancino, P.; Belloni, E.; Gullo, C.; Ciotti, M. Therapeutic efficacy of
1302   a *Coriolus versicolor*-based vaginal gel in women with cervical uterine high-risk HPV Infection: A retrospective
1303   observational study. *Adv. Ther.*, **2021**, *38*, 1202-1211.

1304 195. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.;
1305   Salminen, S.; Calder, P.C.; Sanders, M.E. Expert consensus document. The International Scientific Association
1306   for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat.*
1307   *Rev. Gastroenterol. Hepatol.*, **2014**, *11*, 506-514.

1308 196. Suez, J.; Zmora, N.; Segal, E.; Elinav, E. The pros, cons, and many unknowns of probiotics. *Nat. Med.*, **2019**,
1309   *25*, 716-729.

1310 197. Liu, C.T.; Chu, F.J.; Chou, C.C.; Yu, R.C. Antiproliferative and anticytotoxic effects of cell fractions and
1311   exopolysaccharides from *Lactobacillus casei* 01. *Mutat. Res.*, **2011**, *721*, 157-62.

1312 198. Reis, S.A.D.; da Conceição, L.L.; Peluzio, M.D.C.G. Intestinal microbiota and colorectal cancer: changes in the
1313   intestinal microenvironment and their relation to the disease. J. Med. Microbiol., 2019, 68, 1391-1407.

1314 199. Molska, M.; Reguła, J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal
1315   cancer. *Nutrients*, **2019**, *11*, 2453.

1316 200. Lu, K.; Dong, S.; Wu, X.; Jin, R.; Chen, H. Probiotics in cancer. *Front. Oncol.*, **2021**, *11*, 638148.

1317 201. Hassan, Z. Anti-cancer and biotherapeutic potentials of probiotic bacteria. *J. Cancer Sci. Ther.*, **2019**, *11*, 9-13.

202. Singh, B.; Mal, G.; Marotta, F. Designer probiotics: Paving the way to living therapeutics. *Trends Biotechnol.*, **2017**, *35*, 679-682.

203. Bedada, T.L.; Feto, T.K.; Awoke, K.S.; Garedew, A.D.; Yifat, F.T.; Birri, D.J. Probiotics for cancer alternative prevention and treatment. *Biomed. Pharmacother.*, **2020**, *129*, 110409.

204. Hibberd, A.A.; Lyra, A.; Ouwehand, A.C.; Rolny, P.; Lindegren, H.; Cedgård, L.; Wettergren, Y. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. *BMJ Open Gastroenterol.*, **2017**, *4*, e000145.

205. Consoli, M.L.; da Silva, R.S.; Nicoli, J.R.; Bruña-Romero, O.; da Silva, R.G.; de Vasconcelos Generoso, S.; Correia, M.I. Randomized clinical trial: impact of oral administration of *Saccharomyces boulardii* on gene expression of intestinal cytokines in patients undergoing colon resection. *JPEN J Parenter. Enteral Nutr.*, **2016**, *40*, 1114-1121.

206. Naito, S.; Koga, H.; Yamaguchi, A.; Fujimoto, N.; Hasui, Y.; Kuramoto, H.; Iguchi, A.; Kinukawa, N.; Kyushu University Urological Oncology Group. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. *J. Urol.*, **2008**, *179*, 485-490.

207. Seely, D.; Ennis, J.E.; McDonell, E.; Fazekas, A.; Zhao, L.; Asmis, T.; Auer, R.C.; Fergusson, D.; Kanji, S.; Maziak, D.E.; Ramsay, T.; Chamberland, P.; Spooner, C.; Threader, J.; Seely, A. Intervention development process for a pragmatic randomized controlled trial: The thoracic peri-operative integrative surgical care evaluation trial. *J. Altern. Complement. Med.*, **2019**, *25*, S112-S123.

208. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry. Early clinical trials with live biotherapeutic products: Chemistry, manufacturing, and control information. www.fda.gov/downloads/Biologi%E2%80%A6/UCM292704.pdf , **2016**.

209. Charbonneau, M.R.; Isabella, V.M.; Li, N.; Kurtz, C.B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. *Nat. Commun.*, **2020**, *11*, 1738.

210. O'Toole, P.W.; Marchesi, J.R.; Hill, C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. *Nat. Microbiol.*, **2017**, *2*, 17057.

211. Ulsemer, P.; Henderson, G.; Toutounian, K.; Löffler, A.; Schmidt, J.; Karsten, U.; Blaut, M.; Goletz, S. Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium *Bacteroides ovatus* D-6. *Cancer Immunol. Immunother.*, **2013**, *62*, 875-887.

212. Ulsemer, P.; Toutounian, K.; Kressel, G.; Goletz, C.; Schmidt, J.; Karsten, U.; Hahn, A.; Goletz, S. Impact of oral consumption of heat-treated *Bacteroides xylanisolvens* DSM 23964 on the level of natural TFα-specific antibodies in human adults. *Benef. Microbes.*, **2016**, *7*, 485-500.

Codice campo modificato

45

1349   213. Ho, C.L.; Tan, H.Q.; Chua, K.J.; Kang, A.; Lim, K.H.; Ling, K.L.; Yew, W.S.; Lee, Y.S.; Thiery, J.P.; Chang,
1350   M.W. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. *Nat. Biomed.*
1351   *Eng.,* **2018**, *2*, 27-37.

1352   214. Arthur, J.C.; Gharaibeh, R.Z.; Uronis, J.M.; Perez-Chanona, E.; Sha, W.; Tomkovich, S.; Mühlbauer, M.; Fodor,
1353   A.A.; Jobin, C. VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated
1354   colorectal cancer. *Sci. Rep.*, **2013**, *3*, 2868.

1355   215. Veiga, P.; Suez, J.; Derrien, M.; Elinav, E. Moving from probiotics to precision probiotics. *Nat. Microbiol.*,
1356   **2020**, *5*, 878-880.

1357   216. Sotoudegan, F.; Daniali, M.; Hassani, S.; Nikfar, S.; Abdollahi, M. Reappraisal of probiotics' safety in human.
1358   *Food Chem. Toxicol.*, **2019**, *129*, 22-29.

1359   217. Cammarota, G.; Ianiro, G.; Tilg, H.; Rajilić-Stojanović, M.; Kump, P.; Satokari, R.; Sokol, H.; Arkkila, P.;
1360   Pintus, C.; Hart, A.; Segal, J.; Aloi, M.; Masucci, L.; Molinaro, A.; Scaldaferri, F.; Gasbarrini, G.; Lopez-
1361   Sanroman, A.; Link, A.; de Groot, P.; de Vos, W.M.; Högenauer, C.; Malfertheiner, P.; Mattila, E.;
1362   Milosavljević, T.; Nieuwdorp, M.; Sanguinetti, M.; Simren, M.; Gasbarrini, A. European consensus conference
1363   on faecal microbiota transplantation in clinical practice. *Gut*, **2017**, *66*, 569.

1364   218. Ianiro, G.; Mullish, B.H.; Kelly, C.R.; Kassam, Z.; Kuijper, E.J.; Ng, S.C.; Iqbal, T.H.; Allegretti, J.R.; Bibbò,
1365   S.; Sokol, H.; Zhang, F.; Fischer, M.; Costello, S.P.; Keller, J.J.; Masucci, L.; van Prehn, J.; Quaranta, G.;
1366   Quraishi, M.N.; Segal, J.; Kao, D.; Satokari, R.; Sanguinetti, M.; Tilg, H.; Gasbarrini, A.; Cammarota, G.
1367   Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. *Gut*, **2020**, *69*, 1555.

1368   219. Gupta, A.; Saha, S.; Khanna, S. Therapies to modulate gut microbiota: Past, present and future. *World J.*
1369   *Gastroenterol.*, **2020**, *26*, 777-788.

1370   220. Rezasoltani, S; Yadegar, A.; Asadzadeh Aghdaei, H.; Reza Zali, M. Modulatory effects of gut microbiome in
1371   cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors. *Cancer Med.,* **2021**,
1372   *10*, 1141-1154.

1373   221. Baruch, E.N.; Youngster, I.; Ben-Betzalel, G.; Ortenberg, R.; Lahat, A.; Katz, L.; Adler, K.; Dick-Necula, D.;
1374   Raskin, S.; Bloch, N.; Rotin, D.; Anafi, L.; Avivi, C.; Melnichenko, J.; Steinberg-Silman, Y.; Mamtani, R.;
1375   Harati, H.; Asher, N.; Shapira-Frommer, R.; Brosh-Nissimov, T.; Eshet, Y.; Ben-Simon, S.; Ziv, O.; Khan,
1376   M.A.W.; Amit, M.; Ajami, N.J.; Barshack, I.; Schachter, J.; Wargo, J.A.; Koren, O.; Markel, G.; Boursi, B. Fecal
1377   microbiota transplant promotes response in immunotherapy-refractory melanoma patients. *Science*, **2021**, *371*,
1378   602-609.

1379 222. Davar, D.; Dzutsev, A.K.; McCulloch, J.A.; Rodrigues, R.R.; Chauvin, J.M.; Morrison, R.M.; Deblasio, R.N.;
1380   Menna, C.; Ding, Q.; Pagliano, O.; Zidi, B.; Zhang, S.; Badger, J.H.; Vetizou, M.; Cole, A.M.; Fernandes, M.R.;
1381   Prescott, S.; Costa, R.G.F.; Balaji, A.K.; Morgun, A.; Vujkovic-Cvijin, I.; Wang, H; Borhani, A.A.; Schwartz,
1382   M.B.; Dubner, H.M.; Ernst, S.J.; Rose, A.; Najjar, Y.G.; Belkaid, Y.; Kirkwood, J.M.; Trinchieri, G.; Zarour,
1383   H.M. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. *Science*,
1384   **2021**, *371*, 595-602.
1385 223. Zhang, T.; Lu, G.; Zhao, Z.; Liu, Y.; Shen, Q.; Li, P.; Chen, Y.; Yin, H.; Wang, H.; Marcella, C.; Cui, B.; Cheng,
1386   L.; Ji, G.; Zhang, F. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical
1387   findings, animal studies and in vitro screening. *Protein Cell.*, **2020**, *11*, 251-266.
1388 224. Zhang, T.; Ding, X.; Dai, M.; Zhang, H.; Xiao, F.; He, X.; Zhang, F.; Zhang, X. Washed microbiota
1389   transplantation in patients with respiratory spreading diseases: Practice recommendations. *Med. Microecol.*,
1390   **2021**, *7*, 100024.
1391 225. Chen, D.; Wu, J.; Jin, D.; Wang, B.; Cao, H. Fecal microbiota transplantation in cancer management: Current
1392   status and perspectives. *Int. J. Cancer.*, **2019**, *145*, 2021-2031.
1393 226. Zhu, X.; Goldberg, A. Introduction to semi-supervised learning. *Morgan Claypool Publ.*,
1394   https://doi.org/10.2200/S00196ED1V01Y200906AIM006 , **2009**.
1395 227. Moreno-Indias, I.; Lahti, L.; Nedyalkova, M.; Elbere, I.; Roshchupkin, G.; Adilovic, M.; Aydemir, O.; Bakir-
1396   Gungor, B.; Santa Pau, E.C.; D'Elia, D.; Desai, M.S.; Falquet, L.; Gundogdu, A.; Hron, K.; Klammsteiner, T.;
1397   Lopes, M.B.; Marcos-Zambrano, L.J.; Marques, C.; Mason, M.; May, P.; Pašić, L.; Pio, G.; Pongor, S.;
1398   Promponas, V.J.; Przymus, P.; Saez-Rodriguez, J.; Sampri, A.; Shigdel, R.; Stres, B.; Suharoschi, R.; Truu, J.;
1399   Truică, C.O.; Vilne, B.; Vlachakis, D.; Yilmaz, E.; Zeller, G.; Zomer, A.L.; Gómez-Cabrero, D.; Claesson, M.J.
1400   Statistical and machine learning techniques in human microbiome studies: Contemporary challenges and
1401   solutions. *Front. Microbiol.*, **2021**, *12*, 635781.
1402 228. Bonetta, R.; Valentino, G. Machine learning techniques for protein function prediction. *Proteins*, **2020**, *88*, 397-
1403   413.
1404 229. Vamathevan, J.; Clark, D.; Czodrowski, P.; Dunham, I.; Ferran, E.; Lee, G.; Li, B.; Madabhushi, A.; Shah, P.;
1405   Spitzer, M.; Zhao, S. Applications of machine learning in drug discovery and development. *Nat. Rev. Drug.
1406   Discov.,* **2019**, *18*, 463-477.
1407 230. McCarthy, J.F.; Marx, K.A.; Hoffman, P.E.; Gee, A.G.; O'Neil, P.; Ujwal, M.L.; Hotchkiss, J. Applications of
1408   machine learning and high-dimensional visualization in cancer detection, diagnosis, and management. *Ann. N.
1409   Y. Acad. Sci.*, **2004**, *1020*, 239-362.

231. Kerlikowske, K.; Scott, C.G.; Mahmoudzadeh, A.P.; Ma, L.; Winham, S.; Jensen, M.R.; Wu, F.F.; Malkov, S.; Pankratz, V.S.; Cummings, S.R.; Shepherd, J.A.; Brandt, K.R.; Miglioretti, D.L.; Vachon, C.M. Automated and clinical breast imaging reporting and data system density measures predict risk for screen-detected and interval cancers: A case-control study. *Ann. Intern. Med.,* **2018**, *168*, 757-765.

232. Nam, J.G.; Park, S.; Hwang, E.J.; Lee, J.H.; Jin, K.N.; Lim, K.Y.; Vu, T.H.; Sohn, J.H.; Hwang, S.; Goo, J.M.; Park, C.M. Development and validation of deep learning-based automatic detection algorithm for malignant pulmonary nodules on chest radiographs. *Radiology*, **2019**, *290*, 218-228.

233. Pantuck, A.J.; Lee, D.K.; Kee, T.; Wang, P.; Lakhotia, S.; Silverman, M.H.; Mathis, C.; Drakaki, A.; Belldegrun, A.S.; Ho, C.M.; Ho, D. Modulating BET bromodomain inhibitor ZEN-3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE.AI, an artificial intelligence platform. *Adv. Therap.*, **2018**, *1*, 1800104.

234. Ngiam, K.Y.; Khor, I.W. Big data and machine learning algorithms for health-care delivery. *Lancet Oncol.*, **2019**, *20*, e262-e273.

235. Marcos-Zambrano, L.J.; Karaduzovic-Hadziabdic, K.; Loncar Turukalo, T.; Przymus, P.; Trajkovik, V.; Aasmets, O.; Berland, M.; Gruca, A.; Hasic, J.; Hron, K.; Klammsteiner, T.; Kolev, M.; Lahti, L.; Lopes, M.B., Moreno, V.; Naskinova, I.; Org, E.; Paciência, I.; Papoutsoglou, G.; Shigdel, R.; Stres, B.; Vilne, B.; Yousef, M.; Zdravevski, E.; Tsamardinos, I.; Carrillo de Santa Pau, E.; Claesson, M.J.; Moreno-Indias, I.; Truu, J. Applications of machine learning in human microbiome studies: A review on feature selection, biomarker identification, disease prediction and treatment. *Front. Microbiol.,* **2021**, *12*, 634511.

236. Ai, D.; Pan, H.; Han, R.; Li, X.; Liu, G.; Xia, L.C. Using decision tree aggregation with random forest model to identify gut microbes associated with colorectal cancer. *Genes (Basel)*. 2019, 10, 112.

237. Gupta, A.; Dhakan, D.B.; Maji, A.; Saxena, R.; P K, V.P.; Mahajan, S.; Pulikkan, J.; Kurian, J.; Gomez, A.M.; Scaria, J.; Amato, K.R.; Sharma, A.K.; Sharma, V.K. Association of *Flavonifractor plautii*, a Flavonoid-Degrading Bacterium, with the gut microbiome of colorectal cancer patients in India. *mSystems*, **2019**, 4, e00438-19.

238. Jang, B.S.; Chang, J.H.; Chie, E.K.; Kim, K.; Park, J.W.; Kim, M.J.; Song, E.J.; Nam, Y.D.; Kang, S.W.; Jeong, S.Y.; Kim, H.J. Gut microbiome composition is associated with a pathologic response after preoperative chemoradiation in patients with rectal cancer. *Int. J. Radiat. Oncol. Biol. Phys.*, **2020**, 107, 736-746.

239. Kharrat, N.; Assidi, M.; Abu-Elmagd, M.; Pushparaj, P.N.; Alkhaldy, A.; Arfaoui, L.; Naseer, M.I.; El Omri, A.; Messaoudi, S.; Buhmeida, A.; Rebai, A. Data mining analysis of human gut microbiota links *Fusobacterium* spp. with colorectal cancer onset. *Bioinformation*, **2019**, *15*, 372-379.

1441   240. Zimmermann, M.; Zimmermann-Kogadeeva, M.; Wegmann, R.; Goodman, A.L. Mapping human microbiome
1442   drug metabolism by gut bacteria and their genes. *Nature*, **2019**, *570*, 462-467.

1443   241. Sharma, A.K.; Jaiswal, S.K.; Chaudhary, N.; Sharma, V.K. A novel approach for the prediction of species-
1444   specific biotransformation of xenobiotic/drug molecules by the human gut microbiota. *Sci. Rep.*, **2017**, *7*, 9751.

1445   242. Maier, L.; Pruteanu, M.; Kuhn, M.; Zeller, G.; Telzerow, A.; Anderson, E.E.; Brochado, A.R.; Fernandez, K.C.;
1446   Dose, H.; Mori, H.; Patil, K.R.; Bork, P.; Typas, A. Extensive impact of non-antibiotic drugs on human gut
1447   bacteria. *Nature*, **2018**, *555*, 623-628.

1448   243. Zimmermann, M.; Patil, K.R.; Typas, A.; Maier, L. Towards a mechanistic understanding of reciprocal drug-
1449   microbiome interactions. *Mol. Syst. Biol.*, **2021**, *17*, e10116.

1450

1451

1452 **Figures/Illustrations**

1453

1454 **Figure 1. Characterization of the gut microbiome in cancer onset and response to anticancer therapies in order to**

1455 **develop novel personalized microbiome-based intervention strategies**. An unbalanced gut microbial ecosystem and

1456 its metabolites may be involved in the development of cancer, as well as in a poor response to anticancer therapy. The

1457 collection and analysis of biological samples (e.g., feces, blood and urine) through novel sequencing-based and

1458 metabolomic approaches, as well as bioinformatic tools, are needed to gain knowledge about the microbiome, cancer and

1459 anticancer therapies. In particular, machine learning approaches have great potential in enabling the development of

1460 personalized microbiome-based interventions (*i.e.,* prebiotics, probiotics and FMT), which, through the activation of the

1461 host immune system, could favor the response to therapy and tumor clearance.

1462

1463 **Tables:**

1464 **Table 1**. Clinical trials registered in the last two years on ClinicalTrials.gov (as accessed on July 2021) concerning the application of prebiotics, probiotics, and fecal microbiota
1465 transplantation (FMT) as adjuvant therapy in cancer patients. Search terms included "cancer", in combination with "prebiotics", "probiotics" or "FMT".

1466

	Title	**Status**	**Results**	**Condition**	**Intervention**	**Location**	**URL**
Prebiotics	Impact of Dietary Fiber as Prebiotics on Chemotherapy-related Diarrhea in Patients With Gastrointestinal Tumors	Recruiting	Not available	Chemotherapy-related Diarrhea	Dietary supplement with prebiotic fiber + loperamide hydrochloride vs. maltodextrin + loperamide hydrochloride	China	https://ClinicalTrials.gov/show/NCT04447443
	Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance	Recruiting	Not available	Squamous Intraepithelial Lesions of the Cervix, Human Papilloma Virus Infection, Cervix Lesion	PAPILOCARE® device	France	https://ClinicalTrials.gov/show/NCT04624568
Probiotics	Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer	Not yet recruiting	Not available	Breast Cancer	Novel probiotic vs. placebo	United States	https://ClinicalTrials.gov/show/NCT04362826
	Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer	Not yet recruiting	Not available	Anatomic Stage I, IA, IB, II, IIA, IIB, III, IIIA, IIIB, IIIC Breast Cancer AJCC v8	Dietary supplement with probiotic	United States	https://ClinicalTrials.gov/show/NCT04857697
	Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC	Recruiting	Not available	Non-small Cell Lung Cancer Stage III	dietary supplementation with probiotics, nivolumab +paclitaxel (albumin-bound type) + carboplatin AUC5	China	https://ClinicalTrials.gov/show/NCT04699721
	The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage II	Not yet recruiting	Not available	Lung Cancer, Gastric Cancer, Esophageal Cancer	Dietary supplement with probiotic (Pro12)	Canada	https://ClinicalTrials.gov/show/NCT04871412
FMT	Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders	Not yet recruiting	Not available	Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV, IVA, IVB, IVC Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8	FMT + nivolumab, FMT + pembrolizumab	United States	https://ClinicalTrials.gov/show/NCT04729322

Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy	Active, not recruiting	Not available	Lung Cancer	FMT + anti-PD1 therapy vs. anti-PD-1 therapy	Spain	https://ClinicalTrials.gov/show/NCT04924374
Washed Microbiota Transplantation for The Treatment of Oncotherapy-Related Intestinal Complications	Recruiting	Not available	Intestinal Complications, Cancer	Washed Microbiota Transplantation (WMT)	China	https://ClinicalTrials.gov/show/NCT04721041
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic Melanoma or NSCLC	Not yet recruiting	Available	Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV	FMT	Israel	https://ClinicalTrials.gov/show/NCT04521075
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation	Not yet recruiting	Not available	Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Chronic Lymphocytic Leukemia	FMT	France	https://ClinicalTrials.gov/show/NCT04935684
The IRMI-FMT Trial	Not yet recruiting	Not available	Malignant Melanoma Stage III, Malignant Melanoma Stage IV	Allogenic FMT vs. autologous FMT	Austria	https://ClinicalTrials.gov/show/NCT04577729
Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma	Recruiting	Not available	Renal Cell Carcinoma	FMT vs. placebo	Italy	https://ClinicalTrials.gov/show/NCT04758507

1467